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“ASSOCIATION BETWEEN TESTOSTERONE 
LEVEL AND CORONARY ARTERY DISEASE” 
 
 
 
 
 
 
 
  
                                                         INTRODUCTION 
              Coronary Artery Disease has become as the primary reason for death in the 
world.
(1,2,3) 
Researchers climb that by 2030, death from Coronary Artery Disease will 
be more globally
(2)
. 
              World Health Organisation had estimated that 17 million persons perished 
of Cardio Vascular Disease in 2004 and there will be nearly 20 million Cardio 
Vascular Deaths worldwide every year and 24 million deaths by 2030. Each year, 
there are about 5.8million new Coronary Artery Disease cases and nearly 40 million 
persons with established Coronary Artery Disease are living today.
(3)
 
            Testosterone is the principal androgen in the circulation, which is synthesized 
and secreted mainly by Leydig cells.
(4,5)
 Testosterone effects include 
vasodilatation
(4,6)
 and amelioration of coronary ischemia and also potentially 
deleterious effects.
(4)
 
            It is broadly acknowledged that men encounter a steady drop in their level of  
testosterone along with increasing age, and male sex for a long time viewed as a 
strong threat feature for developing Coronary Artery Disease. Altogether, these two 
details have driven various researchers to seek for a probable correlation among 
endogenous testosterone concentration and Coronary Artery Disease.
(7)
 
           The rapid vasodilatory impact of testosterone concentration on the Ischemic 
Myocardium in patients suffering from Coronary Artery Disease is credited to a 
direct non genomic outcome of androgens on vascular cells.
(8)
 
  
            Hypogonadism is associated with the increased level of blood sugar, 
increased level of triglycerides, high body mass index, high waist to hip ratio, 
increased total body fat mass, increased fasting insulin resistance index which are all 
the risk factor for developing Cardiovascular Disease.
(9)
 
 
            Risk factors of Cardiovascular Disease, which may be influenced by 
Testosterone includes Vascular tone, Serum Lipoprotein profile, Platelet count, Red 
Blood Cell counts and the development of Atherogenesis. Most epidemiological 
studies states that higher serum Testosterone levels corresponds with lesser Cardio 
Vascular Disease threat in men.
(9)
 
          Testosterone affects the arterial wall - Prostaglandin system, which favours the 
vasoconstriction and platelet aggregation when there is thrombaxane formation.
(6)
 
          Emerging evidences indicates a crucial part of androgens in cardiovascular 
health of men. In this study, we demonstrate that whether or not serum testosterone 
concentration in men who have Coronary Artery Disease is lesser than the Normal 
Coronary Vasculature. 
 
 
 
 
 
  
                                                   AIMS AND OBJECTIVES 
 
 To evaluate the difference between the Plasma Sex Hormone and Coronary 
Artery Disease in patients undergoing Coronary Angiography and in matched 
controls. 
 
 To determine whether levels of androgens vary among the men with and men 
without Coronary Artery Disease. 
 
 
 
 
 
 
 
 
 
 
            
  
                                             REVIEW OF LITERATURE 
ANATOMY OF CORONARY ARTERIES 
               The  heart obtains their blood supply through two major coronary arteries 
normally. The Right branch of the coronary artery generally provides the right 
ventricle and atrium and the Left branch of the Coronary Artery provides the left 
ventricle and atrium arising from the ascending aorta from its anterior and left 
posterior sinuses.
(10) 
 
                                         ANATOMY OF CORONARY ARTERIES 
 
 
                                                       FIGURE 1 
  
LEFT CORONARY ARTERY: 
                  Left sinus of Valsalva nearby its upper border gives rise to the left 
coronary artery (LCA), at about the level of the open border of the valve cusp. The 
LCA has a short (0.5-2 cm) common stem that bifurcates or trifurcates usually.
(10,11) 
 
                  First branch, the anterior interventricular (descending) branch, courses 
downward in the anterior interventricular groove which is largely embedded in thick 
fat, which encircles the acute border of the heart just to the right side of the apex, and 
ascends up to the posterior interventricular groove. The left anterior descending 
branch of the LCA provides branches to the adjacent side of the anterior Right 
Ventricular wall which usually anastomose with branches from the right coronary 
artery and septal branches which supply anterior two thirds and apical portions of 
septum, and also supplies the number of divisions to the anteroapical segments of the 
left ventricle, which includes the anterior part of the papillary muscle. One of the 
septal branch originating from the upper third of the anterior interventricular branch 
is usually larger than the others, which gives nutrients to the midseptum, and also the 
bundle of His and the conductive system of the branches of the bundle. This branch 
also may supply the anterior part of the papillary muscle of right ventricle through  
moderator band.
(10)
  
                             The second branch of the left coronary artery is the smallest 
circumflex branch which passes through the left AtrioVentricular sulcus. It branches 
off to the upper lateral portion of the left ventricular wall and to the left atrium. The 
circumflex branch usually terminates at the obtuse margin of the heart, but it can 
  
reach the crux which is the junction of posterior interventricular sulcus and posterior 
AtrioVentricular groove. If the circumflex branch reaches the crux, it supplies the 
entire left ventricle and the septum of the ventricles, with or without the right 
coronary artery.
(10)
 
                             The Third branch, if  LCA trifurcates, coming off amongst the 
anterior interventricular branch and the circumflex branch, is merely an Left 
Ventricle branch that originates from the main artery. 
RIGHT CORONARY ARTERY: 
                             The right anterior sinus of Valsalva of the aorta gives rise to the 
right coronary artery (RCA), which passes besides right AtrioVentricular sulcus. The 
right coronary artery encircles the acute border to get into the crux in the majority of 
cases. It branches off to various amount to the anterior side of the Right Ventricle 
wall. The posterior interventricular descending branch move downwards along with 
the posterior interventricular groove, and provides nutrients to the posterior third of 
the interventricular septum. The diaphragmatic part of the right ventricle is largely 
supplied by small, parallel branches from the marginal and posterior descending 
arteries, and not from the parent vessel itself. 
(10,11)
 
                                Commonly, the posterior papillary muscle of the left ventricle 
have double blood supply from left and the right coronary artery. Of the right atrial 
divisions of right coronary artery, one is of great importance. This branch originates 
from the RCA shortly after its takeoff and ascends along the right atrium on the 
anteromedial border. It enters through the upper part of atrial septum, reappears as 
  
the superior vena cava branch as nodal artery, posterior and to left side of the 
Superior Vena Cavae ostium, rounds the ostium which runs closer towards the 
sinoatrial node, and providing the branches off to the crista terminalis and pectinate 
muscles.
(10)
 
BRANCHING PATTERN VARIATIONS 
                               In Human Heart, variations in the branching pattern are extremely 
common. In aound 67% of the cases, the Right Coronary Artery transverses the crux 
and provides portion of the Left Ventricular wall and the septum of the ventricules. 
Over 15% of cases, as seen in dogs and many other mammals the LCA circumflex 
branch passes the crux, by giving away the posterior interventricular branch, which 
providing the entire left ventricle, the ventricular septum, and portion of the RV wall. 
Over 18% of cases, together both coronary arteries access the crux. No real posterior 
interventricular branch may exist, but the posterior septum is penetrated at the 
posterior interventricular groove by many branches from the LCA, RCA, or both. In 
about 40% of cases the SVC branch is a continuation of a large anterior atrial branch 
of the LCA rather than of the anterior atrial branch of the RCA. 
(10)
 
                                  Also, the first branch of the RCA may originate independent of 
the right sinus of Valsalva rather than from the parent artery. Rarely, the second or 
even the third RCA branch arises independently.
(10,11)
 
CORONARY DOMINANCE: 
                                  Coronary Dominance refers to the Coronary Artery which 
branches off the Posterior Interventricular Artery. Right dominance occurs when the 
  
posterior interventricular artery emerge after the right coronary artery which is 80%. 
Left dominance occurs when posterior interventricular artery arises from left 
coronary artery which is 10%. Co-Dominance occurs when the posterior 
interventricular artery is moulded together with both right and left coronary arteries 
which is 10%.
(12)
 
 CORONARY VEINS: 
                                   Most of the coronary veins enter the coronary sinus. The three 
largest veins are the great cardiac, middle cardiac and posterior left ventricular vein. 
The Ostia of these veins may be guarded by fairly well developed unicuspid or 
bicuspid valves. The oblique vein of Marshall of the left atrium enters the sinus near 
the orifice of the great cardiac vein. Its ostium never has a valve. Independently, the 
right atrium receives the small cardiac vein and the anterior cardiac veins always do. 
Small venous systems in the atrial septum and probably in ventricular walls and 
septum enter the cardiac chambers directly, called the thebesian veins.
(11)
 
CORONARY CIRCULATION 
                                      The circulation of the coronary system is exceptional as they 
are accountable to produce the arterial pressure as it is necessary to perfuse the 
systemic circulation on the whole and also has its own perfusion impeded during the 
cardiac cycle.
(13)
 
                                    Although, Heart is less than that of 0.5% of total body weight, 
it obtains around 5% of the cardiac output at rest. The heart normally uses oxidative 
phosphorylation to generate the ATP required to pump blood. However, of all the 
  
oxygen that the heart consumes, no more than 40% reflects the oxidation of 
carbohydrate, remaining 60% of myocardial oxygen consumption in the fasting state 
is due to the oxidation of fatty acids. The myocardium readily oxidizes ketone 
bodies, which can provide considerable energy throughout starvation or 
DiabeticKetoAcidosis. When the Oxygen supply is adequate, the heart oxidises both 
lactate and pyruvate, as do red skeletal muscle fibres, although the arterial 
concentration of pyruvate is usually low.
(14)
 
                             Contraction of the Myocardium is directly related to the oxygen 
supply. The stability involving both oxygen demand and oxygen supply is the vital 
risk marker for the function of the heart.
(13)
 
                             When the energy demand for ATP exceeds the supply of Oxygen 
by diseases affecting coronary blood flow, the heart can no longer take up lactate but 
instead releases lactate by breaking down its own glycogen stores. In this manner, the 
heart can continue to function for a short time when it is deprived of O2. Nociceptive 
fibres triggers the sense of referred pain, if there is hypoxia in the myocardium, 
which is  known as angina pectoris. Prolonged or more severe insult of the 
myocardial tissue, results ultimately in necrosis, which is known as myocardial 
infarction. This precipitates a vicious cycle, in which ischemia-provoked contractile 
dysfunction, that further  attenuates hypotension and further ischemia.
(13,14)
 
                             The branches of Left Coronary artery course on top of the heart, 
branching into segments that penetrate into the tissue and dividing into capillary 
networks. Capillary density in histological sections of the human heart exceeds 
  
3000/mm2 as skeletal muscle has only 400/mm2. The small diameter which is <20 
μm of cardiac muscle fibres is lesser than the skeletal muscle which is 50 μm. The 
cardiac muscle fibres facilitates O2 diffusion into the cardiac cells, which have a 
high energetic demand.
(5)
 
                               Once blood passes through the capillaries, it collects in venules, 
which drain outward from the myocardium to converge into the epicardial veins. 
These veins empties in right atrium by the coronary sinus. Other vascular channels 
drain directly into the cardiac chambers which includes the thebesian veins. Because 
the deoxygenated blood carried by the thebesian veins exits predominantly into the 
ventricles, this blood flow bypasses the pulmonary circulation. Numerous collateral 
vessels among branches of the arterial vessels and throughout the venous system act 
as anastomoses. These provide alternative routes for blood flow when a primary 
vessel become occluded.
(10,14)
 
EXTRAVASCULAR COMPRESSION: 
                         In systemic circulation, blood flow roughly parallels the pressure 
grade in the aorta, rising in systole and falling in diastole. But, in the coronary 
circulation, flow is somewhat paradoxical. Although the heart is the source of its own 
perfusion pressure, myocardial contraction effectively squeezes its own blood flow. 
Hence, the profile of vascular supply by coronary arteries is mainly dependent on the 
aortic perfusion pressure and the extra vascular compression resulting from the 
contracting ventricles, particularly the left ventricle.
(14)
 
  
                            In the left coronary artery, transiently blood flow may actually 
reverse in early systole  as the force of the left ventricle‘s isovolumetric contraction 
compresses the left coronary vessels, while the aortic pressure has not yet begun to 
rise as aortic valve is still closed. As aortic pressure increases later during systole, 
coronary blood flow increases but never reaches peak values. However, early during 
diastole, when the relaxed ventricles no longer compress the left coronary vessels 
and aortic pressure is still high, left coronary flow rises rapidly to extremely high 
levels. Around 80% of total left coronary vascular supply strikes during diastole.
(14)
 
                            Contrastingly, the profile of vascular supply by way of the right 
coronary artery matches the pressure profile of its feed vessel, the aorta. Here, 
systole contributes a greater proportion of the total flow, and systolic reversal does 
not occur. The reason for this difference is developed by the right side of the heart 
because of the lower wall tension, as it pumps against lower resistance of the 
pulmonary circulation and does not occlude the right coronary vessels during 
contraction. At the onset of  lethal arrhythmia, left coronary perfusion briefly raises, 
which reflects the loss of mechanical compression of vasculature. Due to the 
variation in the heart rate, the duration of diastole more than the systole is affected 
and also affects the coronary flow. In the course of tachycardia, the fraction of the 
cardiac cycle spent in diastole decreases, minimizing the phase accessible for utmost 
left coronary perfusion. If the heart is healthy, the coronary vessels can adequately 
enlarge in reaction to the metabolic signals caused by increased cardiac work, which 
offsets the negative outcome of the shorter diastole. Conversely, an increased heart 
rate can be risky when severe coronary artery disease limits blood flow.  Coronary 
  
vascular supply alters in time during the cardiac cycle and it also alters along with 
depth in the heart wall. Blood flows to myocytes of the heart through arteries that 
penetrate from the epicardium in the direction of endocardium.
(14)
 
                              The intramuscular pressure is more aound the endocardium and 
less around the epicardium during the systole. All things being equal, the perfusion 
of the endocardium would therefore be less than that of the epicardium. However, 
total blood flows to the endocardial and epicardial halves are approximately equal, as 
the endocardium has a lesser intrinsic vascular resistance. Hence there is increased 
blood flow during diastole. When the diastolic pressure at the aortic root is 
pathologically low or coronary arterial resistance is high, endocardial blood flow 
falls below the epicardial flow. Thus, the inner wall of the left ventricle often 
experiences the greatest damage with atherosclerotic heart disease.
(14)
 
MYOCARDIAL METABOLISM: 
                               Coronary circulation has a striking mark, which is the nearly 
linear connection amongst oxygen consumption of myocardium and myocardial 
vascular supply.  In a resting individual, each 100 g of heart tissue receives 60 to 70 
mL/min of vascular supply. Normally, the myocardium takes out 70% to 80% of the 
oxygen of arterial blood which is normally 20 mL/dL blood, thereby producing an 
extremely low venous O2 content which is 5 mL/dL. Therefore, the heart may not 
react in response to bigger metabolic demands by taking out much more oxygen than 
it already has, when the individual is at rest. The heart can meet large increases in O2 
demand only by increasing coronary blood flow, which can exceed 250 mL/min per 
100 g with exercise. Because blood pressure normally varies within fairly narrow 
  
limits, the only way to substantially increase blood flow through the coronary 
circulation during exercise is by vasodilatation. The heart relies primarily on 
metabolic mechanisms to increase the calibre of its coronary vessels. Adenosine has 
received particular emphasis in this regard. A rise in the metabolic action of the 
myocardium, which results in deficit of the coronary blood flow or drop in the 
myocardial PO2, which results in adenosine release. Further, Adenosine diffuses into 
the Vascular Smooth Muscle Cells, stimulating purinoceptors to provoke 
vasodilatation by means of decreasing [Ca2+]i. Thus, inadequate perfusion to a 
region of tissue would elevate interstitial adenosine levels, which causes 
vasodilatation and restore the blood flow to the affected region.
(14)
 
                                  When cardiac demand outstrips the blood supply, a brief 
increase in [K+]o, may play a vital role for the initial rise in coronary perfusion. 
However, it is unlikely that K+ mediates sustained elevations in blood flow. When 
oxygen demand overrides oxygen supply, the increase in the PCO2 and the decrease 
in PO2 lowers the coronary vascular resistance. 
                              Coronary vascular supply is relatively stable between perfusion 
pressures of 70mm Hg and more than 150 mm Hg. Thus, like that of the brain, the 
blood flow to the heart exhibits auto regulation. In addition to the myogenic response 
which contributes to the coronary auto regulation, fluctuations in adenosine and PO2 
also plays an important role.
(14,15)
 
SYMPATHETIC STIMULATION: 
      Sympathetic nerves follows the arterial supply, coursing throughout the heart. 
Stimulation of these nerves causes the heart to beat more frequently and more 
  
forcefully. β1 Adrenoceptors on the cardiac myocytes mediate these chronotropic 
and inotropic responses. As discussed in the previous section, the increased 
metabolism of the myocardium leads on to coronary vasodilatation through 
metabolic pathways. However, during pharmacological inhibition of the β1 receptors 
on the cardiac myocytes, which prevents the increase in metabolism, sympathetic 
nerve stimulation causes a coronary vasoconstriction. This response is the direct 
effect of sympathetic nerve action on α adrenoceptors of the coronary resistance 
vessels. Thus, blocking of β1 receptors exposes adrenergic vasoconstriction. But, 
under normal circumstances, the tendency of the metabolic pathways to vasodilate 
far overwhelms the tendency of the sympathetic pathways to vasoconstrict.
(14,15)
 
                            Stimulation of the vagus nerve has merely a weak vasodilatory 
effect on the coronary resistance vessels. This muted response is not due to 
insensitivity of the resistance vessels to acetylcholine, which elicits a pronounced 
vasodilatation when it is administered directly. Rather, the release of acetylcholine 
from the vagus nerve is restricted to the vicinity of the sinoatrial node. Thus, the 
vagus nerve has a much greater effect on heart rate than on coronary resistance.
(14,15)
 
COLLATERAL VESSEL GROWTH: 
                          When a coronary artery or one of its primary branches becomes 
abruptly occluded, ischemia can produce necrosis (i.e., a myocardial infarct) in the 
region deprived of blood flow, as discussed earlier. However, if a coronary artery 
narrows gradually over time, collateral blood vessels may develop and at least 
partially ameliorate the reduced delivery of O2 and nutrients to the compromised 
area, preventing or at least diminishing tissue damage. Collateral vessels originate 
  
from existing branches that undergo remodelling with the proliferation of endothelial 
and smooth muscle cells. Stimuli for collateral development include angiogenic 
molecules released from the ischemic tissue and changes in mechanical stress in the 
walls of vessels supplying the affected region.
(14)
 
CORONARY STEAL: 
                               A variety of drugs can promote vasodilatation of the coronary 
arteries. These are typically prescribed for patients suffering from angina pectoris, 
the chest pain associated with inadequate blood flow to the heart. If the build-up of 
atherosclerotic plaque, which underlies angina pectoris—occurs in the large 
epicardial arteries, the increased resistance lowers the pressure in the downstream 
micro vessels. Under such conditions, the physician should be cautious in using 
pharmacological agents to dilate the coronary vessels. In an ischemic area of the 
myocardium downstream from a stenosis, metabolic stimuli may have already 
maximally dilated the arterioles. Administration of a vasodilator can then only 
increase the diameter of blood vessels in non ischemic vascular beds that are parallel 
to the ischemic ones. The result is coronary steal, a further reduction in the pressure 
downstream from the site of stenosis and further compromise of the blood flow to the 
ischemic region. When vasodilator therapy relieves angina, the favourable result is 
more likely to be attributable to the vasodilatation of the non coronary systemic 
vessels, which reduces peripheral resistance, thereby reducing the after load during 
systole and thus the work of the heart.
(14)
 
 
 
  
CORONARY ARTERY DISEASE: 
                            Coronary Artery Disease is due to the pathological changes in the 
arteries which causes insufficient coronary blood flow
(15,16)
. Death occurs suddenly 
due to the acute occlusion of the coronary artery or fibrillation of the heart, while 
some casualty happens due to the progressive weakening of the heart pumping, 
gradually around the time of weeks to years.
(15)
 CAD can cause myocardial ischemia 
by three mechanisms:  
(1) profound vascular spasm,  
(2) formation of atherosclerotic plaques, and  
(3) thromboembolism. 
                       Vascular spasm is an atypical spastic condition, in which transiently 
contracts the coronary vessels. Vascular spasms are connected along with the earlier 
phases of CAD and are most often instigate by exposing to cold climate, physical 
effort or anxiety. Commonly, this state is reversible, which do not last long in order 
to damage the cardiac muscle. When only very less oxygen is obtainable in the 
coronary vessels, the endothelium discharges platelet-activating factor (PAF). PAF, 
which exerts a variety of actions, was named for its first discovered effect, activating 
platelets. Among its other effects, endothelium releases PAF, which diffuses into the 
vascular smooth muscle and by making it to contract and bringing the vascular 
spasm.
(16)
 
                         Atherosclerosis is a degenerative and gradually developing arterial 
pathology, which directs to the occlusion of distressed vessels, which decreases 
vascular supply by them. Atherosclerosis is categorised by plaques, which is formed 
  
beneath the vessel lining within walls of the artery. An atherosclerotic plaque has a 
lipid rich core enclosed by an unusual overgrowth of smooth muscle cells, which is 
covered  by a collagen rich connective tissue cap. It projects into the vessel lumen, as 
the plaque emerges. These are the following complex sequence of events in the 
gradual Development of Atherosclerosis: 
1. Atherosclerosis commences with the blood vessel wall damage that triggers an 
inflammatory reaction, which sets the point for plaque accumulation. Normally, 
inflammation is a defensive reaction, in which battle infection and encourages patch 
up of damaged tissue. However, persistent and low-grade inflammatory reaction over 
a course of decades, can insidiously head on to arterial plaque development and then 
lead on to the heart disease, if the source of the damage stays inside the vessel wall. 
Plaque formation likely has many causes. Suspected artery-abusing agents that has 
vascular inflammatory reaction includes free radicals, oxidised LDL cholesterol, 
elevated blood pressure, homocysteine, chemicals discharged from fat cells or even 
bacteria and viruses that damages the vessel walls. Oxidised LDL cholesterol 
considered to be the most common causative factor for Atherosclerosis.  
2. Initially atherosclerosis is characterized by the deposition of excessive quantity of 
low-density lipoprotein cholesterol under the endothelium, that is moreover 
suspected as bad cholesterol, in combination with a protein carrier. Since LDL 
deposits inside the vessel wall, this cholesterol product turns into oxidized, mainly by 
oxidative wastes which are free radicals produced by the blood vessel cells. 
  
 3. Due to the occurence of oxidized LDL, it reacts on the endothelial cells to 
generate the chemicals,which draws monocytes to the injured site. These immune 
cells activates the local inflammatory response. 
4. When they comes out of the blood and goes into the blood vessel wall, monocytes 
remains there permanently and transform into vast phagocytic cells known as 
macrophages. Macrophages voraciously phagocytise the oxidized LDL, till all these 
cells develop into crowded with fatty droplets which looks foamy over the 
microscope. These foam cells, which engorges the macrophages, deposit under the 
vessel lining which develops into a obvious fatty streak, the commencement of an 
atherosclerotic plaque. 
5. The most primitive stage of a plaque is deposition of a cholesterol rich residue 
under the endothelium. Further, the disease advances as smooth muscle cells inside 
the vessel wall, which migrates on topmost site of the lipid growth from the muscular 
layer of the blood vessel which is just beneath the endothelium. This migration is 
activated by chemicals emitted from the inflammatory site. From their recent 
location, the smooth muscle cells carry on to break up and extend, inducing 
atheromas, which are the benign tumours of the smooth muscle cells inside the blood 
vessel walls. Maturing plaque is formed all together from the lipid rich residue and 
overlying smooth muscle. 
6. When it continues to advance, the plaque gradually protrudes into the lumen of the 
blood vessel. The protruding plaque tapers the cavity from which the blood flows. 
7. Oxidized LDL obstructs the release of nitric oxide from the endothelial cells, 
which further contribute to the narrowing of blood vessel. Nitric oxide is a local 
  
chemical messenger, which relaxes the underlying layer of normal smooth muscle 
cells inside the blood vessel wall. Relaxation of these smooth muscle cells helps to 
dilate the blood vessel. Due to the reduction in the nitric oxide release, vessels which 
are injured by developing plaques, cannot dilate  normally. 
8. A condensing plaque also get involves with the nutrient replacement for cells 
positioned inside the arterial wall, which leads on to wall erosion around the areas of 
the plaque. The damaged area is encroached by fibroblasts, and  forms a collagen 
rich connective tissue cap above the plaque. Sclerosis is the extreme progression of 
fibrous connective tissue, therefore it is called as atherosclerosis, which is 
characterized by atheromas and sclerosis along with odd lipid deposition. 
9. In the later periods of the disease, Ca2+ frequently deposits in the plaque. The 
blood vessel so badly affected develop into hard and cannot distend easily.
(16)
 
         A most common location for the growth of atherosclerotic plaques is the initial 
few centimetres of the two major coronary arteries.
(15)
 
COMPLICATIONS OF ATHEROSCLEROSIS 
                  Atherosclerosis damages the arteries all over the body, however the 
crucial concerns include the impairment of the brain and heart vessels. 
Atherosclerosis is the most important reason for developing stroke, while it causes 
the myocardial ischemia in the heart. The following are the capable complications of 
coronary atherosclerosis: 
■ Angina pectoris:  
             Gradual swelling of projecting plaque carry on to taper the vessel lumen and 
gradually reduces coronary blood flow, which urges frequent increasing spells of 
  
brief myocardial ischemia, which is the capacity to correspond blood flow with 
cardiac oxygen requirement becomes very restricted. Even though the heart is not 
normally ―felt‖, pain is related to the myocardial ischemia. Such cardiac pain is 
called as angina pectoris, which is felt under the sternum, which also radiates to the 
left shoulder and along the left arm. The symptoms of the angina pectoris recur 
whenever there is an increase in the cardiac oxygen demand because of the coronary 
blood flow. For instance, heavy exertion or emotional stress. The ischemia linked 
with the typically transient angina strike, which is mostly interim and also reversible, 
which is reduced by rest, vasodilator drugs such as nitro-glycerine.
(16)
 
THROMBOEMBOLISM:  
                         The enlarging atherosclerotic plaque can break through the damaged 
endothelial coating , exposing blood to the underlying collagen of the plaque. Foam 
cells discharges the chemicals that can loosen the fibrous cap of a plaque by breaking 
the connective tissue fibres. Plaques, which has thicker fibrous caps are considered 
stable because they do not rupture. However, plaques which has thinner fibrous caps 
are considered to be unstable, so they are most likely to rupture and trigger clot 
formation. Normally, blood platelets does not stick on to smooth, healthy vessel wall. 
But when platelets is brought in contact with collagen at injured vessel, they adhere 
to it and help to promote the blood clot formation. Moreover, foam cells produce a 
potent clot promoter. An atypical blood clot adhered to the blood vessel wall is called 
thrombus. The thrombus progressively enlarges, till it totally obstructs the vessel or 
the constant course of blood flowing on the thrombus makes it very loose. As it leads 
downstream, such a freely floating clot obstructs entirely a minor vessel. Thus, 
  
atherosclerosis results in a slow or rapid blockage of a coronary vessel by means of 
thromboembolism.
(16)
 
■ Myocardial Infarction: 
             Following the complete obstruction of a coronary vessel, the cardiac tissue 
aided by the vessel dies immediately from oxygen scarcity and infarction appears, if 
not the area is perfused from the collateral blood vessels. During a heart attack, the 
extent of the injured area relies on the extent of the choked blood vessel. When the 
obstruction is larger in the vessel, the area deprived of blood supply also becomes 
larger. When there is complete obstruction of any one of the main branches, 
concludes in wide spread myocardial injury. Left coronary artery blockage is mainly 
obliterating than the right, as it provides blood supply to 85% of the cardiac tissue.
(16)
 
               A heart attack has four possible consequences: instant casualty, gradual 
casualty from difficulties, entirely functional recovery and recovery with weakened 
function.
(16)
 
 
FACTORS AFFECTING ATHEROSCLEROSIS:
 (16)
  
               In spite of the solid association amongst cholesterol and heart disease, more 
than half of the cardiac patients have a normal lipid profile and no other well 
determined threat features. 
            Obviously, these cardiac patients have other features that are concerned in the 
advancement of Coronary Artery Disease. Further, these similar features contributes 
to develop the atherosclerosis in those people with poor cholesterol levels. 
 
  
                  
                     FIGURE 2   ATHEROSCLEROTIC PLAQUE FORMATION 
 
            The following are among the leading other possible risk factors: 
■ Elevated blood concentration of the amino acid homocysteine was recently  
implicated as a strong predictor for heart disease. Homocysteine is composed as a 
transitional product during metabolism of the essential dietary amino acid 
methionine. Investigators believe homocysteine contributes to atherosclerosis by 
encouraging rapid growth of vascular smooth muscle cells, an early step in 
development of this artery clogging condition. Furthermore, homocysteine appears to 
break the endothelial cells causing oxidation of LDL, both of which can contribute to 
plaque formation. Three vitamin B, that is folic acid, vitamin B12, and vitamin B6, 
which all play key roles in pathways that clear homocysteine from the blood. 
Therefore, these B vitamins are all needed to keep blood homocysteine at safe levels. 
■  Elevated levels of C-reactive protein, which is a blood borne indicator for 
inflammation, is having increased threat to develop coronary artery disease. People 
  
who have higher level of C-reactive protein in their blood were three times more 
suspected to have a heart attack. As inflammation does a vital task in the progression 
of atherosclerosis, anti-inflammatory drugs like aspirin, aids in preventing the heart 
attacks. Moreover, aspirin guards against infarction throughout its function in 
preventing clot formation. 
■ An infectious agent may be the underlying culprit in a significant number of cases 
of atherosclerotic disease. Among the leading suspects are respiratory infection- 
causing Chlamydia pneumonia, herpes virus, and gum-disease-causing bacteria.
(16)
 
CONVENTIONAL ATHEROSCLEROTIC RISK FACTORS:
(13)
 
 Smoking  
 Enhances the oxidation of LDL 
 Dysfunctional endothelial Nitric Oxide Biosynthesis 
 Increases C- Reactive Protein, Homocysteine. 
 Increases Soluble Intercellular Adhesion Molecule-1, Fibrinogen,. 
 Increases monocyte adhesion to endothelial cells, leads to 
spontaneous Platelet Aggregation. 
 Hypertension 
 Systolic Pressure and Pulse Pressure have greater importance than 
Diastolic Blood Pressure in Cardiovascular Disease. 
 Systolic Pressure reflects the reduced arterial Elasticity. Pulse 
Pressure generally reflects Vascular wall stiffness. 
 
  
 Low Density Lipoprotein Cholesterol 
                   -   Involved in the Atherogenesis. 
 High Density Lipoprotein Cholesterol 
                   -  Augments Peripheral catabolism of Cholesterol by Ferrying 
Cholesterol from the vessel wall. 
                  -  Transport Antioxidant enzymes which plays an important role in 
decreasing the quantity of oxidised Phospholipids in Atheromatic lesions. 
 Triglyceride 
                   -  Exposure of the Arterial wall to triglyceride possibly will encourage 
Atherosclerosis. 
 Metabolic Syndrome, Insulin Resistance and Diabetes: 
                   - Accumulation of progressive glycation end products associated with 
Vascular Damage, causing impaired Endothelial and Smooth muscle function. 
                  - Augments Leukocyte bond to Vascular endothelium, which also impairs 
Nitric Oxide mediated Vasodilatation, a critical early step in Atherogenesis.  
 Physical Exercise (No Pain, No Gain) 
                  - Reduces the Myocardial Oxygen demand and increases exercise 
capacity which correlates with lower levels of Coronary risks. 
                  - Reduces Adiposity, Diabetes Incidence, Decreases Blood Pressure. 
  
                  - Improves Dyslipidemia and Vascular Inflammation. 
 Obesity 
                 - Defined as Body Mass Index of 30 or Higher. 
                 - Impact on Vascular risk which is mediated by the interrelations along 
with the Glucose intolerance, Insulin resistance, Hypertension, Physical passivity and 
Dyslipidemia. 
 Mental Stress 
                 - Augments the Myocardial Oxygen requirements and also causes 
Coronary Vasoconstriction. Further linked to Platelet and Endothelial Dysfunction, 
Metabolic syndrome and initiation of Ventricular Arrhythmias. 
 Depression 
                   - Increases the Platelet Activation, Elevates the levels of high sensitivity 
C-Reactive Protein, decreases the Heart Rate. 
NOVEL ATHEROSCLEROTIC RISK FACTORS:
(13)
 
 High Sensitivity C-Reactive Protein, 
 Serum Amyloid A, 
 Homocysteine, 
 Fibrinogen, 
 Tissue Plasminogen Activator (tPA) 
 Lipoprotein (a), 
  
 D- Dimer, 
 Apo lipoprotein B 
 Plasminogen Activator Inhibitor 1 (PAI-1) 
 Interleukin 6 
 Soluble Intercellular Adhesion Molecule-1(sICAM-1) 
                           Other Inflammatory biomarkers like Myeloperoxidase, Soluble CD 
40 ligand and Metalloproteinase are under study as markers of underlying 
atherosclerosis. 
DIAGNOSIS OF CORONARY ARTERY DISEASE:
(13)
 
 Biochemical tests - Fasting Blood Glucose level, serum Creatinine, 
Total Cholesterol, Triglyceride, Low Density Lipoprotein Cholesterol, 
High Lipoprotein Cholesterol, Lipoprotein (a), and Inflammatory 
biomarkers. 
 Cardiac biomarkers Troponin (T or I; cTnT or cTnI) and Creatine 
Kinase MB isoenzyme (CK-MB) 
 Echocardiography 
 Stress test 
o Exercise Electrocardiogram 
o Exercise - Single Photon Emission Computed Tomography(SPECT). 
o Adenosine Single Photon Emission Computed Tomography(Nuclear 
Stress Test) 
o Exercise Echocardiography. 
  
o Dobutamine Echocardiography. 
 Cardiac Magnetic Resonance Imaging (CMR) 
             - Projects efficient recovery subsequently after Percutaneous or Surgical 
revascularisation. 
 Coronary Angiography 
              - American College Cardiology / American Heart Association  guidelines to 
proceed to Coronary Angiography should be based on symptomatic status and risk 
stratification formed on clinical information and non-invasive investigation outcome. 
             - Invasive Technique for the Definitive diagnosis of Coronary Artery Disease 
and precise assessment of its anatomical severity.  
             - Newer Invasive Techniques like Intravascular UltraSonography (IVUS) 
gives a cross sectional analysis of the coronary artery and have substantially 
enhanced the recognition and evaluation of coronary atherosclerosis. And also the 
capability to distinguish the susceptibility of Coronary Atheroma. 
              - Studies incorporating both Coronary Angiography and Intravascular 
UltraSonography have demonstrated that the severity of Coronary Artery Disease 
may be underestimated by doing Angiography alone. 
              - CT Coronary Angiography is also evolving as a non invasive tool as well. 
 
 
  
TREATMENT:
(13)
 
                  American College Cardiology / American Heart Association guidelines 
for the initial medical therapy includes: 
A = Aspirin and Antianginal 
B = Beta Blocker and Blood Pressure 
C = Cholesterol and Cigarette Cessation. 
D = Diet and Diabetes 
E = Exercise and Education 
MEDICAL MANAGEMENT: 
- Healthy Diet 
- Reduction of Coronary risk factors such as smoking cessation, Exercise. 
- Hormone replacement like Estrogens to menopause women and Testosterone to 
Andropause men. 
- Treatment for Associated Diseases like Hypertension, Diabetes, Dyslipidemia 
- Pharmacotherapy for secondary management which includes Aspirin, Clopidogrel, 
Beta Blockers, Angiotensin Converting Enzyme Inhibitors, Antioxidants. 
 
 
  
PHARMACOLOGICAL MANAGEMENT: 
 Nitrates - Nitro-glycerine, Isosorbide Dinitrate, Isosorbide 5- Mononitrate. 
 Beta- Adrenoceptor Blocking agents- Atenolol, Metoprolol, Bisoprolol, 
Propranolol, Labetalol, Carvedilol 
 Calcium Antagonists - Nifedipine, Verapamil, Diltiazem, Amlodipine, 
Felodipine, Nicardipine 
 Ranolazine - Piperazine derivative Antianginal drug. 
 Nicorandil - Nicotinamide ester which possesses nitrate moiety. 
 Ivabradine - Specific and selective inhibitor of Funny current (If) ion channel 
 Fasudil - Orally Available inhibitor of rho kinase. 
OTHER THERAPIES: 
 Spinal cord stimulation - Indicated for refractory angina cases who are unfit to 
do revascularisation by using a improved electrode into the epidural space. 
 Enhance External Counter Pulsation - One of the optional treatment for 
Refractory Angina. 
 Chelation : No benefit in the treatment of Coronary Artery Disease. 
PERCUTANEOUS CORONARY INTERVENTION: 
- Percutaneous Transluminal Coronary Angioplasty, Stenting and related techniques 
represents an important therapeutic option in the management of Coronary Artery 
Disease. 
 
  
CORONARY ARTERY BYPASS SURGERY: 
 Portal access Coronary Artery Bypass Surgery is performed using limited 
incisions with femoral-femoral Cardiopulmonary Bypass and induced cardiac 
arrest. 
 Totally Endoscopic Enabled Coronary Artery Bypass Surgery to be done on 
the arrested heart. 
 Off pump Coronary Artery Bypass Surgery is done using a standard median 
sternotomy with generally small skin incisions and stabilisation devices to 
reduce the motion of the target vessels while anastomoses are performed 
without  Cardiopulmonary Bypass. 
 Minimally Invasive Direct Coronary Artery Bypass is operated through a left 
anterior thoracotomy without  Cardiopulmonary Bypass.
(13,17) 
 TESTOSTERONE: 
               Testosterone is the chief hormone of the testes. It is a vital hormone for the 
male reproduction. Primarily, it enables the growth of male reproductive organs in 
fetal life, controls spermatogenesis, guides development of secondary sexual 
characteristics and also maintains male vigour.
(5,15,18)
 
SOURCE: 
               Testosterone is synthesized mainly by the Leydig cells and also secreted 
from adrenal cortex, Ovaries and Placenta. Small amount of testosterone is secreted 
in the female also.
(5,15,18)
 
  
STRUCTURE: 
               Testosterone is a C19 steroid with an –OH group at 17
th
 position. It is 
synthesized from cholesterol in the Leydig cells of the testis. It is also formed from 
androstenedione secreted by the adrenal cortex. Even though the biosynthetic 
pathways in all endocrine tissues that materialise steroid hormones are alike, the 
tissues differs only in the enzyme systems involved in the process. In the Leydig 
cells, 17 α-hydroxylase is present and in the adrenal cortex, 11- and 21-β 
hydroxylases are found.
(5,15,18)
 
                Pregnenolone is converted to Testosterone by two pathways: δ4 and δ5 
pathways. Pregnenolone is therefore hydroxylated in the 17th position in the testis 
and then subjected to side chain cleavage to form dehydroepiandrosterone. 
Androstenedione is produced via progesterone and 17-hydroxyprogesterone as well. 
Dehydroepiandrosterone and androstenedione are then converted to testosterone.
(5,18)
 
                The secretion of testosterone is under the control of Luteinizing 
Hormone(LH), and the mechanism of stimulation of  Leydig cells by LH involves 
increased formation of cAMP via the G protein-coupled LH receptor and Gs. cAMP 
increases the formation of cholesterol from cholesterol esters and the conversion of 
cholesterol to pregnenolone through the activation of protein kinase A.
(5,15,18)
 
SECRETION 
                The testosterone secretion rate is 4 to 10 mg day.  in normal adult males. 
The normal plasma concentration of testosterone is 300-1000 ng/dL in adult males 
and 30-70 ng/dL in adult females. It declines with the age in males.
(5,18)
 
  
TRANSPORT & METABOLISM 
              98% of the testosterone in plasma is bound to protein off which  65% is 
bound to a β -globulin called gonadal steroid binding globulin (GBG) or sex steroid-
binding globulin which also binds estradiol and 33% is bound to albumin. Only 2% 
of testosterone is free in plasma. The free testosterone enters the target tissues in 
which it is converted to its active form DiHydrotestosterone by 5 α Reductase. A 
small amount of circulating testosterone is converted to estradiol by aromatase, but 
most of the testosterone is converted to 17-ketosteroids by 17 β dehydrogenase. The 
principal ketosteroids are androsterone and its isomer etiocholanolone which are 
excreted in the urine. About two thirds of the urinary 17-ketosteroids are of adrenal 
origin, and one third are of testicular origin.
(5,18,19)
 
            While most of the 17- ketosteroids are weak androgens, it is important to 
indicate that not all 17-ketosteroids are androgens and not all androgens are 17- 
ketosteroids. Etiocholanolone has no androgenic activity, and intrinsically 
testosterone is not a 17-ketosteroid.
(5,18,19)
 
ACTIONS 
              Adding up to their actions in the course of development, testosterone and 
other androgens  has an inhibitory feedback effect on pituitary LH secretion, which 
develop and maintain the male secondary sex characteristics. It also has an important 
protein-anabolic and growth-promoting effect and along with FSH, maintain 
spermatogenesis.
(5,18)
 
 
  
SECONDARY SEX CHARACTERISTICS  
             At puberty, boys develop extensive changes in hair distribution, body 
configuration, and genital size are the male secondary sex characteristics. The 
prostate and seminal vesicles expand, and the seminal vesicles begin to emit fructose. 
This sugar appears to act as the chief nutritional source for the spermatozoa. The 
psychic property of testosterone are hard to define in humans, however in trial 
animals, androgens trigger animated and aggressive behaviour. It has effects on 
sexual behaviour also. Even though body hair increases by androgens, scalp hair is 
decreased. Hereditary baldness often fails to develop if not dihydrotestosterone is 
present. 
(5,18,19)
 
ANABOLIC EFFECTS 
               Androgens increases the synthesis and decreases the breakdown of protein, 
which leads to an increase in the degree of growth. It  claims that they cause the 
epiphyses to fuse to the long bones, hence eventually stopping growth, but it now 
appears that epiphysial closure is due to estrogens. Consequently to their anabolic 
properties, androgens affects moderate Na+, K+, H2O,  Ca2+,  SO4–, and PO4 – 
retention. It also increases the size of the kidneys. 
(5,15,19)
 
MECHANISM OF ACTION 
                         Testosterone binds to an intracellular receptor and the receptor - 
steroid complex, which binds to DNA in the nucleus, facilitating transcription of 
several genes. Furthermore, testosterone get transformed into dihydrotestosterone 
(DHT) by 5 α - reductase in some target cells and DHT binds to the similar 
  
intracellular receptor being testosterone. Moreover DHT circulates, with a plasma 
level which is about 10% of the testosterone concentration. Testosterone–receptor 
network are less constant than DHT–receptor complexes in target cells. Hence, DHT 
formation is a method of augmenting the effect of testosterone in target tissues. 
There are  two 5 α - reductases, encoded by different genes. Type 1 5 α -reductase is 
present in skin all over the body and is the forceful enzyme in the scalp. Type 2 5 α -
reductase is present in genital skin, the prostate, and other genital tissues. 
Testosterone–receptor complexes are important for the maturation of wolffian duct 
structures and subsequently for the growth of male internal genitalia, however DHT–
receptor network are vital for the development of male external genitalia. Besides, 
DHT–receptor complexes are mainly responsible for bulging of the prostate and most 
likely of the penis at the time of puberty, also for the facial hair,  acne and the 
temporal recession of the hairline. Conversely, the increase in muscle mass and the 
growth of male sex drive and libido rely mainly on testosterone rather than DHT.
(5,19)
 
TESTICULAR PRODUCTION OF ESTROGENS 
                         Above 80% of the estradiol and 95% of the estrone in the plasma of 
adult men is formed through extragonadal and also extra adrenal aromatization from 
circulating testosterone and androstenedione. The rest comes from the testes. Little 
estradiol in testicular venous blood comes from the Leydig cells, although some is 
furthermore produced as result of  aromatization of androgens within Sertoli cells. In 
men, the plasma estradiol level is 20 to 50 pg/mL and the total production rate is 
approximately 50 µg/ d. In contrary to the condition in women, estrogens production 
moderately increases with aging men.
(5,19)
 
  
CONTROL OF TESTICULAR FUNCTION 
                          FSH is tropic for Sertoli cells. FSH and androgens preserve the 
gametogenic function of the testes. In addition, FSH activates the discharge of 
Androgen Binding Protein (ABP) and Inhibin. Inhibin gives feedback to inhibit FSH 
secretion. LH is tropic for Leydig cells and stimulates the secretion of testosterone, 
which consecutively gives feedback to inhibit LH secretion. Hypothalamic lesions 
produce atrophy of the testes and failure of their function.
(5,19)
 
INHIBINS 
                          Testosterone decreases the plasma LH, but only in large doses and it 
has no effect on plasma FSH. In patients with the atrophy of the seminiferous 
tubules, Plasma FSH is increased, but levels of testosterone and LH secretion are 
normal. These explanation has taken to the search for inhibin, a factor of testicular 
origin which inhibits FSH secretion. There are two inhibins in extracts of testes in 
men and in antral fluid from ovarian follicles in women. They are formed from three 
polypeptide subunits: a glycosylated α subunit and two nonglycosylated β subunits, 
βA and βB. The subunits are formed from precursor proteins. The α  subunit combines 
with βA to form a heterodimer and with βB to form an additional heterodimer, along 
with the subunits connected by disulfide bonds. Both α βA (inhibin A) and α βB 
(inhibin B) inhibit FSH secretion by a direct action on the pituitary, although it now 
appears that it is inhibin B that is the FSH-regulating inhibin. Inhibins are produced 
by Sertoli cells in males and granulosa cells in females.
(5,19)
 
  
                            The heterodimer βA βB and the homodimers βA βA and βB βB are 
also formed. They stimulate rather than inhibit FSH secretion and consequently are 
called activins. Their function in reproduction is unresolved. However, the inhibins 
and activins are units of the TGF β super family of dimeric development factors that 
also includes MIS. Activin receptors have been identified and belong to the 
serine/threonine kinase receptor family. Inhibins and activins are found not only in 
the gonads but also in the brain and other tissues. Within the bone marrow, activins 
are involved in the development of white blood cells. In embryonic life, activins are 
concerned with the formation of mesoderm.
(5,19)
 
                            In plasma, α 2-macroglobulin binds activins and inhibins. In 
tissues, activins bind to a family of four glycoprotein called follistatins. Binding of 
the activins inactivates their physiologic function remain unresolved.
(5,19)
 
GONADOTROPIN-RELEASING HORMONE: 
                              A major share of the control of sexual activities in both the male 
and the female starts through secretion of Gonadotropin-releasing hormone (GnRH) 
by the hypothalamus. This hormone sequentially triggers the anterior pituitary gland 
to emit two other hormones, which are called as Gonadotropic hormones: (1) 
luteinizing hormone (LH) (2) follicle-stimulating hormone (FSH). In turn, LH is the 
primary trigger for the secretion of testosterone by the testes, and FSH mainly 
stimulates spermatogenesis.
(5,19)
 
 
 
  
EFFECT OF GNRH  
                           Arcuate nuclei of the Hypothalamus secretes GnRH, which is a 10-
amino acid peptide. All these neuronal endings terminate predominantly in the 
median eminence of the hypothalamus, where they emit GnRH advancing into the 
Hypothalamic-Hypophysial portal vascular system. Then the GnRH in the 
hypophysial portal blood, is passed to the anterior pituitary gland, and that promotes 
the discharge of the two gonadotropins, LH and FSH. GnRH is secreted once every 1 
to 3 hours periodically a few minutes at a time. The strength of this hormone's spur is 
influenced in two ways: (1) by the frequency of these cycles of emission and (2) by 
the quantity of GnRH released with each cycle.
(5,15,18)
 
                      The anterior pituitary gland which is secreted by LH, occurs in cycles 
with LH following fairly the pulsatile secretion of GnRH. On the contrary, FSH 
secretion increases and decreases only vaguely with each fluctuation of GnRH 
secretion, rather it changes more leisurely over a phase of many hours in reaction to 
longer-span variation in GnRH. Because of the much intense association between 
GnRH secretion and LH secretion, GnRH is moreover broadly identified as LH-
releasing hormone. 
(5,15,18)
 
GONADOTROPIC HORMONES: LH AND FSH 
                        LH and FSH, are secreted by the same cells, which is called as called 
gonadotropes, in the anterior pituitary gland. In the deficiency of GnRH release from 
the hypothalamus, the gonadotropes in the pituitary gland secrete virtually no LH or 
FSH. Both LH and FSH are glycoproteins. They apply their effects on their target 
  
tissues in the testes primarily by initiating the cyclic AMP second messenger system, 
which in turn activates specific enzyme systems in the respective target cells.
(15)
 
STEROID FEEDBACK  
                      The functions of the testes are regulated by steroids, which is the 
current ―Working Hypothesis‖. There is a increase in the pituitary matter and 
secretion of FSH and LH after Castration and hypothalamic lesions inhibit this rise. 
Testosterone inhibits LH secretion by acting directly at the anterior pituitary and also 
through the impediment of the GnRH discharge from the hypothalamus. Inhibin 
inhibits the FSH secretion by acting directly on the anterior pituitary.
(5,18)
 
                           Reacting to LH, some of the testosterone conceded from the Leydig 
cells soaks the seminiferous epithelium and ensures the Sertoli cells to receive the 
peak local concentration of androgen, which is necessary for natural 
spermatogenesis. Systemically managed testosterone does not increase the androgen 
concentration in the testes to a great degree, and it inhibits LH secretion. 
Accordingly, the net effect of systemically administered testosterone is generally a 
decrease in sperm count. Thus, Testosterone therapy has been recommended as a 
means of contraception for Males. However, the dosage of testosterone required to 
suppress spermatogenesis produces sodium and water retention. The likely use of 
inhibins as male contraceptives is now being opened up.
(5,18)
 
 
 
 
  
TESTOSTERONE DECLINE WITH AGE: 
                         Vermeulen et al, Rubens et al, Baker et al, Pirke et al, Purifoy et al, 
Bremner et al, Tenover et al, Gray et al, Ferrini et al, Harman et al  have illustrated a 
drop in androgen levels with advancing age.
(20-29)
 However, contradicting females, 
males do not encounter the highly distinguished, abrupt and sudden drop in sex 
hormone concentration and termination of reproductive ability as their age increases. 
Contradicting the menopause, the ‗andropause‘ usually brings in quite vague clinical 
features, which includes decreased sex drive, fatigue, dryness of the skin, depression 
and deprived attention, features which are frequently considered merely as a usual 
ingredient of the progression of age. Symptoms consists of crumpled dry skin with 
pale outline, receding hairline, muscular atrophy and gynaecomastia. Generally 
Hypogonadism is not diagnosed and not treated, because of the unclear 
characteristics of the symptoms. It is identified in some patients but it is not treated 
owing to a alleged fear concerning harmful iatrogenic consequences on the Heart and 
Prostrate. The natural and impending causes concerned with the drop in testosterone 
concentration with the aging was studied by Harman et al
(29)
. He established that 
both total and free testosterone declined at a steady pace from the third to ninth 
decade in 890 normally healthy men,. As the age increases, the decline in free 
testosterone concentration was notable because of the substantial increase of sex 
hormone binding globulin. All these explanations were not related to obesity, co 
morbid conditions, smoking, medication and ethanol abuse.
(5,15,19)
 
 
 
  
TESTOSTERONE LEVEL AND CORONARY ARTERY RISK FEATURES: 
                 In the past, it was understood that the elevated incidence rate of coronary 
artery disease in men, possibly described by variation in risk factor studies between 
genders. Generally, Men shows behaviour which are considered more harmful for the 
heart by the elevated quantity of smoking and by foods which are more loaded with 
saturated fats.
(30)
 In spite of this, it has been revealed that variation in behavioural 
profiles of men do not report for the extra load on Coronary Artery Disease, which 
was explained by Njolstad et al and Raynor et al
(30,31)
. 
 
                                                      FIGURE 3 
    The development and  progression of Coronary Atherosclerosis and testosterone 
deficiency are greatly impacted by the interrelation of numerous risk features as 
shown in Figure 3. 
  
VISCERAL OBESITY  
          Increased prevalence rate of Testosterone Deficiency with visceral obesity and 
related disorders is seen in men. The hypogonadal - obesity - adipocytokine cycle 
produces a state where testosterone is rapidly metabolized and the hypothalamic-
pituitary axis is impaired and unable to respond and hence replenish testosterone 
levels.
(32)
  
GLUCOSE INTOLERANCE AND DIABETES 
         Diabetes and the metabolic syndrome are major cardiovascular risk factors. 
Testosterone deficiency has a higher prevalence in these conditions and is associated 
with insulin resistance.
 (32)
 
DYSLIPIDEMIA 
              Testosterone deficiency is related with the changes in the Cholesterol level, 
as they are consistent with a pro-atherogenic background. Barrett-Connor et al
(33)
, 
Haffner et al
(34)
, Simon et al
(35)
, Dai et al
(36)
, Heller et al
(37)
 and Hromadova et 
al
(38)
 have found that testosterone has a negative correlation along with Total 
Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides. Healthy and 
diabetic men have a significant positive association relating testosterone and HDL 
cholesterol levels. In healthy young men where hypogonadism was chemically 
induced, testosterone replacement therapy produced a rise in Total Cholesterol and 
LDL cholesterol and a drop in HDL cholesterol. Whitsel et al
(39)
, a meta analysis of 
several studies has demonstrated that testosterone replacement produces a reduction 
in total and LDL cholesterol and a small decrease in HDL cholesterol.
(32)
  
  
COAGULATION  
               Testosterone deficiency is associated with a pro-coaguable state. Major 
clotting factors, that have been shown to be linked to testosterone levels are 
plasminogen-activator inhibitor type one (PAH), fibrinogen and tissue plasminogen 
activator (tPA). Within many cross-sectional analysis, low testosterone levels are 
related together with elevated fibrinogen concentrations.
(32)
 
                Factor VII, which is concerned in the transformation of prothrombin to 
thrombin, associates inversely with testosterone. Myocardial infarction is associated 
with a fall in tPA and rise in PAH levels. These changes are accompanied by a fall in 
testosterone.
(32)
 
               One of the complications of testosterone treatment is a raised haematocrit 
caused by raised erythropoiesis. Polycythaemia is related with hyper viscosity and 
therefore an increased risk of thrombosis. Monitoring of the haematocrit is essential 
to the management of testosterone therapy and the dose can be lowered to reduce 
these changes, A slight elevation of the haematocrit is unlikely to be associated with 
an increased risk however, each patient and their co-morbid state needs to be 
assessed on an individual basis. In recent years there have been unease concerning 
the augmented threat of thromboembolism by hormone substitution therapy in 
women. The evidence in men suggests that this is not the case with testosterone 
replacement therapy and indeed there may be a beneficial effect in hypogonadal 
subjects.
(32)
  
 
  
 HYPERTENSION 
             Men with hypertension have lower testosterone levels than men with normal 
blood pressure. Potentially, testosterone may lower blood pressure with the reduction 
peripheral vascular resistance. There also may be an effect of testosterone on 
activation of the renin-angiotensin system.
(32)
  
ENDOTHELIAL DYSFUNCTION 
               The data on the effects of testosterone on endothelial dysfunction estimated 
on the brachial artery through flow-mediated vasodilatation are conflicting. Further 
research in this area is necessary to clarify that whether Testosterone has favourable 
or adverse outcome on endothelial dysfunction.
(32)
 
TESTOSTERONE AND INFLAMMATION  
                Atherosclerosis is intimately linked with a pro-inflammatory milieu. A 
local inflammatory response is integral to the early stages of the pathogenesis and is 
also involved in the instability of the established plaque. Inflammatory proteins 
which consist of C-reactive protein, Fibrinogen, Interleukin can be raised in the 
circulation of people with atherosclerosis. Little is known regarding the role of 
testosterone on the immune system. Testosterone substitution to treat hypogonadism 
has resulted in an improvement in the systemic lupus erythematosus.
(32)
 
TESTOSTERONE AND ANGINA  
                  Testosterone was first used to treat the Angina in both Males and Females 
in the early 1940s. Jaffe et al
(40)
, a placebo-controlled study in 1977 found that 
  
testosterone treatment in 50 males who had Coronary Heart Disease produced 32% 
decrease in the time towards 1 mm ST-segment inversion by stress treadmill testing 
after 1 month and 51% after 3 months. The study showed as the lesser the baseline 
bio available testosterone, better the favourable result of testosterone treatment on 
the time to ischemia. A further study involving men along with angina and explicit 
hypogonadisrn revealed  that 1 month's treatment with testosterone led to a 74 
seconds amelioration in the time towards 1 mm ST inversion.
(32)
 
                        Acute testosterone administration directly into the coronary 
circulation at cardiac catheterization in humans leads to a rapid vasodilatation and an 
increase in coronary blood flow within 2-3 min of treatment. This effect is dose-
dependent and occurs at testosterone concentrations within the normal physiological 
range. Furthermore an acute intravenous bolus of testosterone before going on to 
exercise stress testing shows in a substantial improvement in ischemia. The 
mechanism mediating the rapid onset of action is non-genomic and is likely to be 
through an action on calcium and potassium voltage-operated channels.
(32)
 
TESTOSTERONE AS A VASODILATOR  
                         The majority of studies using isolated blood vessels in vivo have 
shown that testosterone acts as a vasodilator. Effects of testosterone have been 
demonstrated in isolated human vessels comprising mesenteric and pulmonary 
arteries and more recently, gluteal arteries from subcutaneous skin. After 3 months of 
androgen suppression treatment for prostate cancer, vascular stiffness which was 
measured using pulse-wave analysis increased in the radial artery and the aorta.
(32)
 
  
                           The vasodilatory effect is of rapid-onset, acting within 2-3 min of 
testosterone administration. The speed of action, and the findings that the outcome is 
not blocked by the means of flutamide. Flutamide is a classical androgen receptor 
blocker and persists in the mouse which is testicularly feminized, and also has an 
inactive androgen receptor which strongly suggests that it is not dependent of the 
typical androgen receptor. The effect is also independent of the endothelium nitric 
oxide and cyclo-oxygenase actions. Pharmacological concentrations are required in 
the isolated artery model to elicit the vasodilatory effect However, more recent 
studies on isolated vascular smooth muscle cells have illustrated straight inhibitory 
property on calcium channels at physiological concentrations. The exact mechanism 
by which testosterone mediates its vasodilatatory action may be either through 
activation of potassium channels or blocking calcium channels. Testosterone has 
been shown to activate calcium-sensitive potassium channels and to have a calcium 
antagonistic action. Electrophysiological and microfluorimetry studies in a vascular 
smooth muscle cell line have provided evidence that at physiological concentrations 
testosterone inhibits L-type voltage-gated calcium channels. The inhibitory effect of 
testosterone was also rapid in this system occurring within 2 min. This confirms that 
testosterone alone is blocking these channels and is not dependent on conversion to 
oestradiol. The L-type calcium channel consists of four protein subunits of which the 
main α1c subunit forms the pore. Human embryonic kidney cells transfect with the 
α1c subunit exhibited a similar inhibitory action. This implies that testosterone acts 
as a calcium channel blocker and has a similar action to commonly prescribed 
  
calcium channel blocking agents, such as nifedipine and amlodipine usually used for 
the treatment of angina and hypertension.
(32)
  
                         Testosterone therapy in males with Coronary Artery Disease has been 
revealed to enhance Flow-Mediated Brachial Artery Vasodilatation. It appears 
because of the consequence of nitric oxide discharge on the endothelium. Certain 
variations are evident in the short and longer term. Conversely, hypogonadal men 
who do not have cardiovascular disease have a higher surge and also nitrate-
arbitrated brachial artery vasodilatation. Testosterone substitution leads to a 
restoration of brachial artery reactivity to normal. Ong et al
(41)
 have shown 
conflicting effects of testosterone on brachial artery reactivity. For example, flow-
mediated however not the nitrate-arbitrated brachial artery vasodilatation raises into 
the men, with prostate carcinoma treated with either chemical or surgical 
castration.
(32)
 
 
ENDOGENOUS TESTOSTERONE IN MEN WITH CAD: 
                                 Generally, it is established that males live through a steady drop 
in their testosterone concentration as their age raises
(23-26,28,29)
. And male sex is 
believed to be a potent risk feature for developing Coronary Artery Disease. 
Concurrently, these two data have provoked several researchers to explore a probable 
correlation between testosterone and Coronary Artery Disease. In the past decade, 
the number of data with evidences which associates reduced testosterone 
concentration along with Coronary Artery Disease is progressively emerging. 
  
                               Men with reduced amount of endogenous testosterone are further 
susceptible towards acquiring Coronary Artery Disease during their lifetimes which 
is recommended by the growing body of evidences.
(42-47)
 Although, this is in straight 
disparity from previous studies results which was unsuccessful in obtaining any 
major Correlation among lower testosterone concentration and advancement of the 
Coronary Artery Disease.
(33,48-50)
 There are two key potential complex factors that the 
earlier reports in general were unsuccessful to report. The sub fraction of testosterone 
utilized to execute the investigation and the approach worn to report in favour of 
subclinical Coronary Artery Disease are the key factors. 
                             Usually in the serum of humans, testosterone survives in two 
diverse sub fractions. The biologically dormant structure of testosterone, which is 
firmly linked to SHBG. Hence, they are not capable of binding with the androgen 
receptors.
 (51,52)
 The bio available testosterone which is the biologically functional 
sub fraction of testosterone, is slackly linked towards albumin and liberally flows in 
the blood, which is also called as free testosterone.
(51,52)
 The addition of all 
testosterone sub fractions is referred as Total testosterone. As a result, it is claimed to 
make use of the biologically functional type of testosterone in assessing the relation 
with the Coronary Artery Disease, should yield mostly the authentic outcomes. 
Although, we need further study to ultimately establish whether or not bio available 
testosterone outshines free testosterone like an indicator of hormone action. English 
et al
(43)
 reported evenly for bio available testosterone level and subclinical Coronary 
Artery Disease and he established that statistically significant decreased 
concentration of both bio available and free testosterone in cases with 
  
angiographically confirmed Coronary Artery Disease analogized along with control 
subjects who had normal coronary arteries. Later, the above said statement was 
authenticated by Rosano et al,
(46)
 who proved that the individuals who were 
angiographically confirmed Coronary Artery Disease, had statistically significant  
lesser values of bio available testosterone. 
                                  These results were fixed by the four further studies. Even 
though we have to mark that nobody has explicated together for both bio available 
testosterone level and subclinical Coronary Artery Disease concurrently.
(42,44,45,47)
 
Conversely, negative relationship among testosterone values and the prevalence of 
Coronary Artery Disease was found by certain researchers. While Kabakci et al
(49)
 
conducted the study with total testosterone and free testosterone values to control for 
subclinical Coronary Artery Disease by evaluating Coronary Angiography outcome 
of both patients and controls. This constitutes the major restriction of this analysis, 
since the researchers could not completely assess for the biologically functional 
testosterone. 
 
ENDOGENOUS TESTOSTERONE AND MORTALITY: 
                                   The above stated fall in testosterone in certain men has 
formerly been considered just as role of the biological ageing process. But the latest 
reports reveals that the reduced baseline testosterone concentration is the important 
prognostic indicator used to define mortality, even after managing the consequences 
of co-morbid states. 
  
                                   Hypotestosteronaemia was a indicator for mortality in 6-
months time in a group of 44 aged hospitalised patients, which was reported by 
Shores et al
(53)
. The subsequent analysis showed the same set of people carried out 
the computer programmed study of Veteran‘s Affair‘s Medical record. Further, they 
analysed on 850 males for a 4 to 8 years time, managing for co-morbid states that  
would have influenced mortality like simultaneous cancer. Men with the lower level 
of testosterone had an 88% significant raise in all the source mortality threat, while 
matching up with normal testosterone concentration was also established.  
                                     The In CHIANTI report
(54)  
showed that an age related decline 
in bio available testosterone was connected with enhanced risk of Mortality, in 2007. 
A six-year follow-up survey was done among 410 males who were aged above 65 
years, and established the most distinct and statistically significant outcome, when 
lower testosterone level was related with relative drop in dehydroepiandrosterone 
sulphate and insulin-like growth factor. There is a disparity to men together with all 
the three hormones higher than the men with single, double or triple hormones in the 
least quartiles were augmenting on added chance for fatality. 
                                         Over a period of almost twenty years, Laughlin et al
(55)
, in 
2008, established a considerable drop in the level of bio available testosterone, 
however not the level of total testosterone with age, which was demonstrated on a 
group of 794 men with the average age of 71 years. The mortality risk was higher for 
the males in the least baseline quartile of the levels of total testosterone and bio 
available testosterone matched up together with those, who are in the highest 
quartile. Following the alteration of adiposity, age and lifestyle options, the mortality 
  
risk was 44% more among the least and uppermost quartiles for the total testosterone 
level. 50% more among the minimum and maximum quartiles for the level of bio 
available testosterone in which Hazard Ratio was 1.50 and 95% Confidence Interval 
was 1.15–1.96.  
                                         The European Prospective research on Cancer Norfolk 
study
(56)
,
 
the major study analysing the outcomes of endogenous testosterone 
concentration and mortality, which prospectively examined the death in 11,606 fit 
males due to any reason and Cardiovascular Disease among the forty and seventy 
nine years age group during the follow up period. Around a six to ten years 
observational spell, they found that there was a statistically highly significant 
correlation among the level serum testosterone and mortality owing to all the causes 
which is 825 deaths, cardiovascular disease which is 369 deaths and cancer which is 
304 deaths. P value was less than 0.01 for Cardiovascular mortality, which was 
statistically significant. 
                                          Malkin et al
(57)
 analysed 930 males with angiographically 
verified Coronary Artery Disease were prospectively monitored for a 7 year phase 
and established that a baseline incidence of hypogonadism in this group to be 24%. 
The mortality rate was 21% in the group of androgen deficiency and in the eugonadal 
group, it was only 12%. Lower bio available testosterone concentration, even if not 
the level of total testosterone considerably impacted the all the cause and 
cardiovascular deaths following this analysis, which proposes that it is the most 
precise test in order to identify pathological defect and threat matched along with the 
former tests. Hence, lower level of testosterone seems to be a indicator for Mortality. 
  
 TESTOSTERONE AND CONGESTIVE CARDIAC FAILURE: 
                                         In the Western Countries, Coronary Artery Disease is the 
prime core source for cardiac failure. Still, precise association among testosterone 
and cardiac failure was not reported to the similar extent like association among 
Testosterone and Coronary Artery Disease. Cardiac failure is regarded as a catabolic 
condition by the initiation of maladaptive neurohormonal stimulation, inflammatory 
cytokines and vasodilator inability. Testosterone makes use of the outcome, which 
resists these alterations, as discussed earlier. In men with cardiac failure, Positive 
association of Cardiac output with the concentration of Serum Testosterone was 
revealed. Acute and intravenous management of testosterone intensively raised 
cardiac output in one of the analysis. 
(58)
 
                                       Analysis was done on the outcomes of frequent use of 
testosterone supplementation. Pugh et al
(58) 
showed developments following twelve 
weeks of testosterone therapy in men with Cardiac failure, in work out ability and in 
clinical symptoms in a small placebo controlled report. In another larger placebo-
controlled report, showed alike outcomes which established with upgrading in work 
out ability, clinical symptoms, maximal strength, insulin resistance, reduction in 
Electrocardiographic Q-T interval and VO2 max.
(57)
 Although these primitive trails 
are positive, further assessment is necessary to clarify the effects of testosterone 
therapy in the cardiac failure and the enduring outcomes of the Testosterone 
replenishment. 
 
 
  
TESTOSTERONE TREATMENT IN CARDIOVASCULAR DISEASE: 
                                         Testosterone therapy is divided into two sets on the basis of 
facts concerning the cardiovascular outcomes. The consequences on cardiovascular 
risk factors, like Hypertension and Dyslipidemia, avails the straightforward clinical 
results of testosterone therapy on the heart itself and the benefit of an indirect 
consequence on Coronary Artery Disease.
(32)
 
                                         In men with type II diabetes, Testosterone replenishment 
has exposed to decrease Total cholesterol, LDL cholesterol and lipoprotein A, yet it 
was found on men who was previously on statin treatment. Testosterone therapy is 
connected with better lipid profiles with the drop in the total cholesterol and LDL 
cholesterol in the analysis of elderly and hypogonadal men.
(59)
 
                                           Arterial hardening and Hypertension are linked along with 
the Hypotestosteronaemia. There were numerous studies on eugonadal, hypogonadal 
and obese men of testosterone substitute therapy and stated that remarkable decline 
in the Systolic and Diastolic pressure during the spell of six months to ten years. 
Alike favourable outcomes of frequent testosterone treatment have revealed in a trail 
of testosterone treatment during the spell of twelve-month in decreasing Body Mass 
Index. In type II diabetic men, Testosterone therapy produces enhanced blood 
glucose control and augmented insulin sensitivity. And also it was found on the trails 
of testosterone therapy that most favourable alterations in the profiles of pro-
inflammatory and anti-inflammatory cytokines.
 (59)
  
                                         Rosano et al
(46)
 demonstrated in a group of men who were 
just ready to carry out the stress treadmill testing and explored the acute outcomes of 
  
testosterone treatment intravenously. Following the intravenous testosterone 
treatment, count to ischaemia was extensively extended, when it was matched up to 
baseline and placebo. 
                                        However, in the perspective of persistent testosterone 
treatment, English et al
(60)
 revealed alike outcomes. In Coronary Artery Disease 
men, who were angiographically confirmed, were given twelve weeks of trans-
dermal testosterone treatment and found that notably augmented count to ischaemia 
following the stress testing. Men with the least testosterone concentration had the 
maximum anti-ischaemic impression. 
                                         Malkin et al
(57)
 executed a alike analysis of Testosterone 
Treatment which progressed the hypothesis, in the men with angina. However 
engaged men only with the substantial hypogonadism. The rise in count to ischaemia 
was more higher in the treadmill analysis. Additionally, there were considerable 
enhancements in clinical features and decrease in the pro inflammatory cytokine that 
is tumour-necrosis factor-A and favourable variations in Cholesterol levels. The anti-
ischaemic consequences of testosterone treatment in an additional analysis, were 
established up to one year. 
                                     Saad et al
(61)
 in a recent review paper, the beneficial 
outcomes on cardiovascular risk features, following testosterone treatment, which 
includes structure of the body, blood pressure, lipid panel and glucose level were 
illustrated. The favourable outcomes started to commence after three months of 
initiating testosterone therapy were demonstrated. Yet, progressing beneficial effect 
was witnessed till nine months in the task of enhancements of blood pressure, twelve 
  
months in the task of better glucose regulation and till two years in the task of 
enhanced cholesterol levels. 
                                       In spite of previous unease on testosterone treatment in men 
with increasing age, currently we have great and promptly rising mass of data, which 
recommends that testosterone substitution in men who have cardiovascular disease is 
secure and efficient. Still, the outcome of testosterone replenishment treatment on the 
overall mortality and patient's benefit shall require some huge, potential and 
randomized studies. The subsequent large action is definitely the attractive part. 
Globally, millions of men are influenced by the Coronary Artery Disease and the 
incidence of hypogonadism were assessed on roughly one-quarter in this population. 
And the prize required to effectively substitute testosterone treatment in the affected 
men are potentially very huge.
 (61)
 
 
ADVERSE EFFECTS OF TESTOSTERONE THERAPY AMONG MEN: 
                             In the past, there were two major worries about testosterone 
treatment among men. The first concern was that it may endorse Coronary Heart 
Disease. The other concern was that the testosterone replenishment treatment may 
induce prostate cancer. Optimistically, there were many recent studies which worked 
with the past concern and also produced guaranteed outcomes, concerning 
physiological amount of testosterone concentration and the men's heart. 
Supraphysiological quantity of testosterone replenishment treatment was utilised in 
an effort to enhance the muscle potency in  a recent trail of fragile hypogonadal men. 
The pharmacological quantity of testosterone has considerably improved muscle 
  
power, however the study was dropped much earlier due to an excessive 
cardiovascular consequences, was also further demonstrated. The authors further 
stated that twenty three patients taking testosterone therapy had cardiovascular 
problems and on this basis the study was discontinued.
(62)
 
                                  Furthermore, they had barely six genuine end points in the 
treatment group, in contrast to only one in the placebo group. Almost half of the 
group had a past record of having cardiovascular disease and the other half had 
substantial cardiovascular threat features. For exact substitution therapy, males with 
hypogonadism must be dealt alone with the physiological dosage of testosterone, was 
demonstrated by this study. It  also described that testosterone substitution should be 
administered in the similar approach like that of thyroid hormone substitution. 
Replenishment doses must be intended to sustain normal physiological 
concentration. In the Basaria study
(62)
, similar or poorer consequences might have 
been observed, if it was completed in hypothyroid patients along with more Coronary 
Artery Disease threat and also, if  the substitution was directed at supra-physiological 
levels. The other upset was probably due to the data that prostate cancer has to be 
effectively managed by androgen suppressive treatment. But, epidemiological and 
clinical analysis have disappointed to establish any correlation among principal 
testosterone concentration and the probability of getting prostate cancer over the last 
decade. Likewise, no trials have proved that lesser than normal testosterone 
concentration are preventive versus getting prostate cancer.
(63)
 
                                 English et al
(60)
 had given testosterone through trans-dermal 
route to the males who had established angina. During the trial period, they observed 
  
the prostate-specific antigen concentration and there was no significant change seen. 
Moreover, testosterone concentration falls along with the increasing age, while the 
incidence of prostate carcinoma ascends.  Testosterone treatment is obviously contra-
indicated in males with prostate cancer and drop in the testosterone concentration are 
favourable. On the other hand, there is no indication from our data, favouring a 
contributory part of testosterone replacement concentration on the physiological 
normal range, along with the probability to progress into the prostate cancer. 
Actually, with the apparent data regarding decreased testosterone level and increased 
mortality, yet it is advised to withhold the testosterone suppressive treatment for the 
aged men who has localized prostate cancer because of decreased survival.
(60,64)
 
                           
ASSOCIATION BETWEEN TESTOSTERONE AND OBESITY: 
                                 The exact process of action of interrelation between testosterone 
and obesity was unidentified. The interrelation of testosterone and obesity might be 
an outcome of the enhancement of lipolysis by testosterone in the adipose tissue of 
abdomen. Furthermore, known that adipose tissue also had an increased 
accumulation of the aromatase enzyme,which might augment the adipose tissue and 
causing in further transformation of testosterone into estrogen, thus resulting 
hypogonadism. On the other hand, by rejecting the hypothalamus-pituitary-testicular 
axis, greater abdominal obesity may result in decreased testosterone discharge. 
Lastly, testosterone is the vital aspect, by stimulating the enzyme 11-hydroxysteroid 
dehydrogenase, it acts on the adipose tissues, by which glucocorticoids might have 
converted into their inactive form.
(65)
 
  
                                  Testosterone Deficiency are also seen in the patients who are 
suffering from chronic diseases like Chronic Kidney Disease, Human Immuno 
Deficiency Virus, Chronic Lung Illness, Diabetes Mellitus and various genetical 
forms like Klinefelter syndrome.
(66,67)
 The other known sources for 
hypotestosteronemia are castration, Trauma, Radiotherapy or chemotherapy, any 
acute conditions and the tumours of Pituitary.
(66,68)
 There is a mystery that whether 
lower level of testosterone in the sick patients, is the source for their sickness or it is 
the outcome of the disease. Reactive oxygen species (ROS) are produced by the 
Leydig cell's mitochondria, which are the standard derivative of testosterone 
synthesis. The deposit of ROS eventually may produce injury to the DNA of the 
Leydig cell, which makes it incompetent to produce testosterone.
(69)
 
 
 
 
 
 
 
 
 
 
  
                                       MATERIALS  AND  METHODS 
                             This study was done at the Department of Physiology, Thanjavur 
Medical College, Thanjavur. The study group was from the General Community in 
and around Thanjavur. The ethical committee approval was obtained for this study. 
The study was case control type and  conducted between October 2015 and May 
2016. The patients were selected from those, who were admitted for diagnostic 
Coronary Angiography. 
                              For this study, Serum Total Testosterone (ng/dL) level, FSH 
(mIU/ml) level and LH (mIU/ml) level were analyzed by ChemiLuminescence 
ImmunoAssay. Patients  underwent  thorough Clinical Examination and Overnight 
Fasting blood samples were taken from 40 male patients referred for diagnostic 
Coronary Angiography, as of symptoms indicative of Coronary Artery Disease and 
40 Control Group of same age group and sex. The quantity of Coronary Artery 
Stenosis was  >50%. The results of Angiogram was reported by the Cardiologist, 
before the Hormonal assay.  
Inclusion criteria: 
 Patients who were referred for Diagnostic Coronary Angiography. 
 Degree of Coronary Artery Stenosis > 50% 
 CRP(<5mg/l) 
Exclusion criteria: 
 Hypogonadism  
 Hypopituitarism 
 Taking drugs that might affect sex hormone level 
  
  High CRP(>5mg/l) 
 Previous Cardiovascular Event 
  Coronary or Periphery Atherosclerosis.         
 Degree of Coronary Artery Stenosis  < 50%. 
 
 
 
                                                   FIGURE 4 
         COBAS 6000 FOR CHEMILUMINESCENCE IMMUNOASSAY 
  
 
                                      FIGURE 5: BLOOD SAMPLES 
                     Venous Blood samples were collected from the subjects, following 
an overnight fasting,  so as to determine the serum and were sent to Bioline 
Laboratory. Serum levels of  Testosterone, FSH and LH were calculated using 
ChemiLuminescence ImmunoAssay by Cobas 6000. Patient's hormone level 
were matched with the healthy control group. 
                   Coronary Angiography was done to establish the incidence of 
Coronary Artery Stenosis. The Coronary Angiography was performed by a skilled 
Interventional Cardiologist in the catheterization laboratory and the outcome was 
reported by an Expert Cardiologist. Significant coronary stenosis and Coronary 
Artery Disease were defined, if there was 50% or more restriction on the lumen 
diameter in at least one of the  major coronary artery. 
    
  
 
    FIGURE 6: CORONARY ANGIOGRAM SHOWING STENOSIS >50% of 
RCA 
                     Body Mass Index was calculated from the measured height and 
weight by using Quetelet's Index.  BMI is measured by dividing weight in 
kilogram by height in meter square.
(8)
 
                           The procedure was explained to all the people who participated in 
this study. Informed written consent was taken from both the controls  and subjects. 
 
 
 
 
 
  
                                                          RESULTS 
                           The continuous variables were stated as mean ± standard 
deviation (SD) and matched up using student‘s t test between CAD and non-CAD 
groups. Categorical variables were described through frequency and percentage 
and were matched up among the above groups. 
                           P value < 0.05 was considered to be statistically significant. 
                           In this case control study, Eighty male subjects(n=80) were 
participated  , which were divided into two groups, as Group A (n=40) and Group B 
(n=40). Group A   includes forty control subjects and Group B  includes forty CAD 
subjects who were referred for diagnostic Coronary Angiography. Serum Total 
Testosterone (ng/dL) level, FSH (mIU/ml) level and LH (mIU/ml) level were 
analyzed for Group A and Group B. 
 
 
  
 
                                                             FIGURE 7 
                        Figure 7 shows the Frequency and percentage of the subjects in this 
study. Group A has the frequency of n=40 and percentage of 50%. Group B has the 
frequency of n=40 and percentage of 50%. 
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DESCRIPTIVE STATISTICS: 
MEAN VALUE FOR BOTH THE GROUPS 
PARAMETERS 
All group (n=80) 
Minimum Maximum Mean 
Standard 
Deviation 
BMI 19.33 30.96 26.0139 2.28173 
FSH (mIU/mL) .15 41.71 6.9348 4.74030 
LH(mIU/mL) 1.68 30.87 6.2873 3.41504 
TESTOSTERONE (ng/ml) .92 15.00 5.9018 2.69335 
 
                                                          TABLE 1 
                               Table 1 shows Mean and the Standard Deviation for  BMI, FSH, 
LH and Testosterone for both the groups. BMI shows the mean value of 26.0139 ± 
2.28173 for both the groups. FSH shows the mean value of 6.9348 ± 4.74030 for 
both the groups.   LH shows the mean value of 6.2873 ± 3.41504 for both the groups. 
TESTOSTERONE shows the mean value of 5.9018 ± 2.69335 for both the groups. 
 
 
 
  
T-TEST  FOR GROUP A AND GROUP B: 
GROUP  MEAN  S.D T DF P VALUE 
BMI      
A (n=40) 25.5165 2.22366 
-1.986 78 
.051>0.05 
Not Significant  B (n=40) 26.5113 2.25700 
FSH (mIU/mL)      
A (n=40) 5.3955 1.58674 
-3.054 78 
.003<0.05 
Significant B (n=40) 8.4742 6.17565 
LH(mIU/mL)      
A (n=40) 5.0090 1.18101 
-3.591 78 
.001<0.05 
Significant B (n=40) 7.5655 4.34484 
TESTOSTERONE (ng/ml)      
A (n=40) 6.8365 2.32962 
3.292 78 
.001<0.05 
Significant B (n=40) 4.9670 2.73400 
 
                                                                  TABLE 2 
                 Table 2 shows t test for the parameters BMI, FSH, LH and Testosterone 
for both Group A and B. The mean BMI of 25.5165 ±2.22366 for Group A and  the 
  
mean BMI of 26.5113 ±2.25700 for Group B. The T = -1.986 with 78 degrees of 
freedom. The P value is 0.051(>0.05) which is not significant. 
                 The mean FSH of 5.3955  ± 1.58674 for Group A and  the mean FSH of 
8.4742 ± 6.17565 for Group B. The T = -3.054 with 78 degrees of freedom. The P 
value is 0.003 (<0.05)  which is significant. 
                  The mean LH of 5.0090  ± 1.18101 for Group A and  the mean LH of 
7.5655 ± 4.34484 for Group B. The T = -3.591 with 78 degrees of freedom. The P 
value is 0.001 (<0.05) which is significant. 
                  The mean TESTOSTERONE of 6.8365 ± 2.32962 for Group A and  the 
mean TESTOSTERONE of 4.9670  ± 2.73400 for Group B. The T = 3.292 with 78 
degrees of freedom. The P value is 0.001 (<0.05)  which is significant. 
 
 
 
 
 
 
  
 
.                                                   FIGURE 8 
 
                   Figure 8 shows Mean and the Standard Deviation for  BMI for both 
Group A and B. The mean BMI of 25.5165 ±2.22366 for Group A and  the mean 
BMI of 26.5113 ±2.25700 for Group B. The P value is 0.051(>0.05) which is not 
significant. 
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                                                    FIGURE 9 
 
                              Figure 9 shows Mean and the Standard Deviation for FSH for both 
Group A and B. The mean FSH of 5.3955  ± 1.58674 for Group A and  the mean 
FSH of 8.4742 ± 6.17565 for Group B. The P value is 0.003 (<0.05)  which is 
significant. 
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                                                       FIGURE 10 
 
                           FIGURE 10 shows Mean and the Standard Deviation for  LH for 
both Group A and B. LH shows the mean value of 6.2873 ± 3.41504 for both the 
groups. The mean LH of 5.0090  ± 1.18101 for Group A and  the mean LH of 7.5655 
± 4.34484 for Group B. The P value is 0.001 (<0.05) which is significant. 
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                                                          FIGURE 11 
 
                           FIGURE 11 shows Mean and the Standard Deviation for  
TESTOSTERONE for both Group A and B. TESTOSTERONE shows the mean 
value of 5.9018 ± 2.69335 for both the groups. The mean TESTOSTERONE of 
6.8365 ± 2.32962 for Group A and  the mean TESTOSTERONE of 4.9670  ± 
2.73400 for Group B. The P value is 0.001 (<0.05)  which is significant. 
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                                                  DISCUSSION 
            Coronary Artery Disease is the most significant source in the world for 
Mortality and Morbidity. Men are prone to have Coronary Artery Disease earlier 
than the women
(2)
.  
            Testosterone is the most powerful male sex hormone. Testosterone is formed 
mainly in the testis and secreted into the bloodstream where it flows and apply 
various effects in peripheral intended organs at different locations. Testosterone can 
carry out its specific task only by binding to the androgen receptor and before that it 
cannot be metabolized into estradiol by aromatase or into dihydrotestosterone by 5a-
reductase. To sustain the proper concentrations of testosterone and its metabolites, a 
vibrant system of numerous interacting factors implicated relating the androgen-
targeted organs has to be in ideal scale.
 (4) 
                 
The actions of testosterone in health and disease is very complicated. There is 
considerable support on the part of testosterone in aging men through metabolic 
syndrome and cardiovascular disease which has wholly altered its insight.
(32)
 
              Low Level of Testosterone concentration is considered as a threat feature for 
developing Coronary Artery Disease
(4)
. Mostly, men with increasing age who have 
Coronary Artery Disease, also have testosterone deficiency and symptoms of 
hypogonadism.
(70)
  
           In this study, Testosterone level was lower in Male patients with Coronary 
Artery Disease. The results of the Testosterone, FSH, LH and BMI were compared 
among the Men with Coronary Artery Disease and Healthy men of same age. 
  
Statistically significant higher value of FSH and LH were found in Coronary Artery 
Disease patients than the Healthy Individuals in this present study. 
             It seems that Phillips et al found the correlations between testosterone level 
and Coronary Artery Disease, increases the possibility in men with 
hypotestosteronemia, is a threat to induce the Coronary Atherosclerosis who have 
undergone Coronary Angiography.
(70)
 
           This study results are similar with Case Control study of English et al, who 
used  TT, FT, BT ,FAI for Analysis and measured Coronary artery disease which 
was confirmed by cardiac catheterization and found that men with Coronary Artery 
Disease have decreased concentration of  BT, FT and FAI. And also higher levels of  
Follicle-Stimulating Hormone and Luteinizing Hormone.
(43)
   
               This study results are consistent with the study of A.Alkamel et al, who 
found that lower serum levels of Testosterone were significantly associated with 
premature CAD. This effect remained significant even after adjustment for other 
well-known cardiovascular threat features, which were also significant predictors 
of the presence of CAD.
(71) 
                              
The results of the present study agreed with the study of Zhao et al 
(CCS, n=201), who used TT for Analysis. He measured Coronary artery disease by 
cardiac catheterization in Twenty seven patients and found that Men with Coronary 
artery disease have decreased levels of Total Testosterone.
(42) 
                            
Dobrzycki et al
(44)
, who used TT, FT, FAI for Analysis and measured 
Coronary artery disease, which was confirmed by cardiac catheterization and found 
  
that Men with Coronary artery disease had decreased concentration of TT, FT, and 
FAI. Similar results were found in the present study.   
                                
Akishita et al
(45)
 (CS, n=171),who used TT for study and 
Cardiovascular events were calculated by H&P, physician and hospital records. They 
found that Men with decreased concentration of TT were most probable to undergo 
the cardiovascular disease. The study results are consistent with the present study.
 
                               
The present study results are parallel to the study of GMC Rosano et 
al (CCS, n=129), who confirmed that a significant correlation exists among 
testosterone level and the degree of coronary atherosclerosis, signifying that depleted 
testosterone levels may be one of the reasons preferably than the consequence of 
cardiovascular disease in men. He used TT, FT, BT, LH, FSH for Analysis. There 
were higher levels of Follicle-Stimulating Hormone and Luteinizing Hormone
(46)
 
                      This study results are similar to the results of Malkin et al, who 
suggested that men with coronary artery disease have the increased frequency of 
testosterone deficiency, which is common.
(57)
 
                        The result of the present study agreed with those of Hu et al (CCS, 
n=87), who used TT for Analysis. He measured cardiac catheterization confirmed 
Coronary artery disease and found that Men with Coronary artery disease have 
reduced concentration of Total Testosterone.
(47)
 
                       But Cauley et al
(48) 
and Kabakci et al
(49)  
found that Testosterone 
level has no association with the Coronary Artery Disease. 
                     Cauley et al
(48)
 who used TT, FT for analysis and measured Coronary 
Artery Disease from nonlethal myocardial infarction, Deaths from Coronary Artery 
  
Disease by the Records and ECG of the Hospital. They found that there was no 
changes in the levels of TT or FT. The main confounding features are Bio available 
Testosterone, which was not utilised for analysis and the Subjects did not go through 
Coronary Angiogram. 
                       Kabakci et al.
(49)
 who used TT, FT  for analysis and measured 
Coronary Angiogram confirmed Coronary artery disease and found that there was no 
statistically significant changes in the levels of FT or TT. The potential confounding 
factors are that Bio available Testosterone was not utilised for the study and Free 
Testosterone was analysed by Suboptimal technique. 
                           Our study reveals that BMI of Coronary Artery Disease patients are 
higher than the Healthy Individuals, but statistically insignificant.         
                           Our study result is consistent with the study of A.Alkamel et al
(71) 
compared BMI (Kg/m2) of Normal coronary subjects 25.82 ± 3.86 with CAD 
patients 26.30 ± 3.60 0.3 and found that it is statistically not significant.(P value - 
0.3) 
                         The result of the present study is similar with study of GMC Rosano 
et al
(46) 
, 
 
who compared CAD patient's BMI (kg/m2) 26.2 with normal subject's BMI   
25.3 and found that it is statistically not significant. 
                        Our study result is similar with the study of Malkin et al
(57) 
matched 
BMI of normal coronaries 27.7 with the Coronary Disease 28.0 and concluded that it 
is statistically not significant.(P -  0.36) 
  
                        Mulligan et al
(65)
 evaluated 1326 normal men along with the 836 
hypogonadal men. The average Body Mass Index was 31.5 for hypogonadal men, 
which was significant when compared with 28.5 for normal men.   
Limitations: 
                           The limitation of this study is that only Total Testosterone were 
used and Free testosterone, Bio-available Testosterone and other sex specific 
Hormones were not measured. Obesity was measured only by BMI. Waist Hip Ratio 
and estimated Visceral Adipose Tissue were not measured.  
        
 
 
 
 
 
 
 
 
 
 
  
                                                         CONCLUSION 
                   The correlation between Testosterone and Coronary Artery Disease is 
statistically significant, which lifts the likelihood that in men with 
hypotestosteronemia are at a risk to develop Coronary Artery Disease.                 
                   The specified evidences proposes that men with Coronary Angiogram 
Confirmed Coronary Artery Disease have decreased concentration of testosterone 
than the healthy men. The outcome of this study is consistent along with the 
evidences that lower levels of testosterone are related along with threat features of 
Coronary Artery Disease. 
                  Currently, it is indefinite that whether low testosterone levels sources 
Coronary Artery Disease or lower concentration of testosterone are a corollary of 
Coronary Artery Disease.  
                  Diminishing levels of testosterone in men are important in the 
development of osteoporosis, sexual dysfunction, and symptoms such as depression 
and fatigue as well, which needs additional evaluation.. 
                    Further studies can analyze the usage of exogenous testosterone in 
men and the efficacy of risk scoring method. These trials must be directed for 
increased threat men with Coronary Heart disease or Diabetes Mellitus or 
Hypertension or Dyslipidemia for the reason that these men have the largest part to 
benefit. The event rates of these men are more and any impact on the therapy, 
positive or negative is more likely to be established inside the borders of a clinical 
study. 
  
                    Obesity can be measured by not only BMI, but also Waist Hip Ratio and 
estimated Visceral Adipose Tissue must be included in future studies. 
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ANNEXURE 
 
 
 
 
 
                                              
                                   
 
PROFORMA 
TOPIC: ASSOCIATION BETWEEN TESTOSTERONE LEVEL AND 
CORONARY ARTERY DISEASE  
 
Study Group/ Control Group  
Name:                                                           Age:                            Sex: Male  
Address: Occupation:  
H/O Present illness:  
Past History: HTN/DM/Cardiovascular Event/ Hypogonadism/ Hypopituitarism  
Personal History: Smoking/ Alcohol/ Drug Intake  
Family History:  
General Examination:  
Height: cm Weight: Kg BMI:  
Anemia: Present/ Not Present  
Cyanosis: Present/ Not Present  
Clubbing: Present/ Not Present  
Jaundice: Present/ Not Present  
Pedal Edema: Present/ Not Present  
Generalized Lymphadenopathy: Present/ Not Present  
Vital signs:  
PR: /min BP: mm Hg RR: /min  
Examination of CVS:  
Examination of RS:  
                                   
 
Examination of Abdomen:  
Examination of CNS:  
Routine Investigation:  
BLOOD SUGAR:        UREA:        URINE ALBUMIN:     URINE SUGAR:      
CRP:  
CORONARY ARTERY STENOSIS: >50% / <50%  
RESULTS: 
 
         PARAMETERS 
 
CONTROL 
 
       CORONARY 
   ARTERY DISEASE 
 
Serum Testosterone  
          (Ng/dL) 
  
 
  Serum Follicle Stimulating 
Hormone (mIU/ml) 
  
   
   Serum Luteinizing Hormone 
            (mIU/ml) 
  
BMI (Kg/m
2
)   
 
                                   
 
ABBREVIATIONS USED IN THE STUDY 
CAD: CORONARY ARTERY DISEASE 
LH: LUTEINIZING HORMONE 
FSH: FOLLICLE-STIMULATING HORMONE 
LCA: LEFT CORONARY ARTERY 
RCA:RIGHT CORONARY ARTERY 
LDL: LOW DENSITY LIPOPROTEIN 
HDL: HIGH DENSITY LIPOPROTEIN 
DHT: DIHYDROTESTOSTERONE 
GnRH: GONADOTROPIN-RELEASING HORMONE 
SHBG: SEX HORMONE-BINDING GLOBULIN 
CCS: CASE CONTROL STUDY 
CS: COHORT STUDY 
TT: TOTAL TESTOSTERONE 
FT: FREE TESTOSTERONE 
BT: BIO AVAILABLE TESTOSTERONE 
FAI: FREE ANDROGEN INDEX 
H&P: HISTORY AND PHYSICAL EXAM 
                                   
 
INFORMED CONSENT FORM 
                  Dr.J.B.Ashraf Ali, Post graduate student in the Department of physiology, 
Thanjavur Medical college, Thanjavur, doing thesis on  “ASSOCIATION 
BETWEEN TESTOSTERONE AND CAD” 
                   I understand the procedure and voluntarily agree to participate in the 
study, I also understand that this study is a non-invasive procedure and the possible 
adverse effects have been explained to me in details clearly in my own language. 
                                                        
                                                                                                Signature of the subject 
                
       Name: 
       Place: 
       Date:  
                                        
 
 
 
 
 
                                   
 
           அராய்ச்சி ஒப்புதல் கடிதம் 
அராய்ச்சி தலைப்பு: டெஸ்டெோஸ்டிடரோன் அளவு மற்றும் இருதய நோடி 
டநோய்க்கு உள்ள டதோெர்பு. 
    தஞ்சை மருத்துவக்கல்லூரி மருத்துவமசையில் ஆடரோக்கியமோை 
நபர்கள் மற்றும் தஞ்சையில் உள்ள இருதய நோடி டநோயோளிகல௃க்கு உள்ள 
டெஸ்டெோஸ்டிடரோன், போளிக்கள் ைிமுடலடிங் ஹோர்டமோன் மற்றும் 
லுடிசைைிங் ஹோர்டமோன் ஆய்வு . 
டபயர் :                                                  டததி : 
வயது :                                                   போல் : 
ஆரோய்ச்ைி டைர்க்சக எண்: 
     இந்த ஆரோய்ச்ைியின் விவரங்கல௃ம் அதன் டநோக்கமும் முழுசமயோக 
எைக்கு டதளிவோக விளக்கப்பட்ெது. எைக்கு விளக்கப்பட்ெ 
விஷயங்கசளப் பற்றி நோன் புரிந்து டகோண்டு எைது ைம்மதத்சத 
டதரிவிக்கிடறன் . 
இந்த ஆரோய்ச்ைியில் பிறரின் நிர்பந்தமின்றி என் டைோந்த விருப்பத்தின் 
டபரில் நோன் பங்கு டபறுகிடறன் மற்றும் நோன் இந்த ஆரோய்ச்ைியிலிருந்து 
எந்டநரமும் பின் வோங்கலோம் என்பசதம௃ம் அதைோல் எந்த போதிப்பும் 
ஏற்பெோது என்பசதம௃ம் நோன் புரிந்துடகோண்டென். இந்த ஆரோய்ச்ைியிைோல் 
ஏற்படும் நன்சமகசளம௃ம் ைில பக்கவிசளவுகசளம௃ம் பற்றி டதளிவோக 
மருத்துவர் மூலம் டதரிந்துடகோண்டென். 
    நோன் என்னுசெய சுயநிசைவுென் மற்றும் முழுைம்மதத்துென் இந்த 
மருத்துவ ஆரோய்ச்ைியில் என்சை டைர்த்து டகோள்ள ைம்மதிக்கிடறன். 
ஆரோய்ச்ைியோளர் சகடயோப்பம்                பங்டகற்போளர் சகடயோப்பம் 
நோள் : 
இெம் : 
                ஆராய்ச்சி தகவல் தாள் 
                                   
 
    தஞ்சை மருத்துவக்கல்லூரி உெலியங்கியல் துசறயில், 
டெஸ்டெோஸ்டிடரோன்,  போளிக்கள் ைிமுடலடிங் ஹோர்டமோன் மற்றும் 
லுடிசைைிங் ஹோர்டமோன் ஆய்வு டமற்டகோள்ளப்படுகிறது . 
    இந்த ஆய்வின் முடிவுகள் ஆடரோக்கியமோை நபர்கள் மற்றும் இருதய 
நோடி டநோயோளிகல௃க்கு உள்ள டெஸ்டெோஸ்டிடரோன்,  போளிக்கள் 
ைிமுடலடிங் ஹோர்டமோன் மற்றும் லுடிசைைிங் ஹோர்டமோன் அளவில் 
உள்ள டவறுபோடுகசள டவளிப்படுத்தும். 
    முடிவுகசள அல்லது கருத்துக்கசள டவளியிடும்டபோடதோ அல்லது 
ஆரோய்ச்ைியின்டபோடதோ தங்களது டபயசரடயோ அல்லது 
அசெயோளங்கசளடயோ டவளியிெமோட்டெோம் என்பசதம௃ம் 
டதரிவித்துக்டகோள்கிடறோம். 
   இந்த ஆரோய்ச்ைியில் பங்டகற்பது தங்கல௃செய விருப்பத்தின் டபரில் 
தோன் இருக்கிறது.   
        டமலும் நீங்கள் எந்டநரமும் இந்த ஆரோய்ச்ைியிலிருந்து பின் 
வோங்கலோம் என்பசதம௃ம் டதரிவித்துக்டகோள்கிடறோம். 
   இரத்த பரிடைோதசையின் முடிவுகள் ஆரோய்ச்ைியின்டபோடதோ அல்லது 
ஆரோய்ச்ைியின் முடிவின் டபோடதோதங்கல௃க்கு அறிவிக்கப்படும் 
என்பசதம௃ம் டதரிவித்துடகோள்கிடறோம். 
 
 
ஆரோய்ச்ைியோளர்  சகடயோப்பம்                 பங்டகற்போளர்  
சகடயோப்பம் 
நோள் : 
இெம் : 
 
 
 
                                   
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
                                   
 
 
                                                               MASTER CHART 
S. NO Group 
 
BMI FSH (mIU/mL) LH(mIU/mL) 
TESTOSTERONE 
(ng/ml) 
1 A 
22.21 2.97 3.24 3.74 
2 A 
27.7 8.87 7.8 3.09 
3 A 
25.14 2.25 4.97 1.89 
4 A 
20.83 8.99 5.05 2.61 
5 A 
26.63 3.54 4.92 2.74 
6 A 
25.56 9.91 8.8 3.21 
7 A 
19.33 4.72 4.8 3.8 
8 A 
24.16 3.47 5.18 4.3 
9 A 
24.69 8.4 3.6 11.58 
10 A 
25.96 6.4 4.6 5.7 
11 A 
23.52 4.5 5.4 6.2 
12 A 
26.79 6.1 6.3 7.2 
13 A 
23.03 5.5 5.6 6.9 
14 A 
25.71 3.9 4.6 5.3 
                                   
 
15 A 
25.71 4.4 5.4 5.8 
16 A 
25.72 4.3 4.7 6.4 
17 A 
27.28 4.6 3.9 7.2 
18 A 
29.17 5.9 5.8 5.9 
19 A 
24.62 5.1 4.7 6.4 
20 A 
24.09 4.9 5.8 6.8 
21 A 
26.87 6.2 6.3 7.9 
22 A 
23.03 3.6 4.6 8.5 
23 A 
24.68 5.7 3.6 8.9 
24 A 
29.41 4.8 4.5 9.6 
25 A 
23.8 5.6 3.5 7.5 
26 A 
25.84 5.6 4.8 7.8 
27 A 
25.59 4.9 5.1 6.9 
28 A 
24.22 5.8 6.2 8.9 
29 A 
26.5 6.9 5.6 11.2 
30 A 
25.52 6.6 6.1 9.2 
31 A 
27.55 4.5 3.7 6.8 
                                   
 
32 A 
23.22 5.5 4.2 8.7 
33 A 
27.81 5.4 4.1 7.5 
34 A 
24.52 4.3 5.6 6.9 
35 A 
29.03 4.6 3.5 7.6 
36 A 
24.44 4.6 3.2 9.1 
37 A 
27 5.7 6.5 8.7 
38 A 
28.9 5.2 4.3 9.4 
39 A 
26.49 6.1 5.4 9.1 
40 A 
28.39 5.5 4.4 6.5 
41 B 
24.91 0.637 3.16 11.58 
42 B 
25.8 4.8 11.24 2 
43 B 
25.03 0.151 3.57 15 
44 B 
27.66 12.21 11.94 7.22 
45 B 
27.94 1.42 1.68 0.92 
46 B 
26.07 5.31 7.76 3.72 
47 B 
26.67 3.66 5 3.41 
48 B 
30.96 5.35 13.6 1.35 
                                   
 
49 B 
28.86 41.71 30.87 3.03 
50 B 
28.78 11.09 7.48 7.47 
51 B 
26.42 3.1 5.54 4.96 
52 B 
23.22 12.93 10.28 2.6 
53 B 
30.83 11.2 4.8 4.7 
54 B 
25.61 10.5 7.8 2 
55 B 
28.01 11.5 6.7 7.6 
56 B 
26.37 11.6 7.6 7.22 
57 B 
24.52 6.8 6.7 0.92 
58 B 
29.4 7.8 7.1 3.72 
59 B 
25.6 8.4 8.9 3.41 
60 B 
26.98 9.5 7.4 1.35 
61 B 
25.63 10.2 6.9 3.03 
62 
B 26.29 9.7 6.8 7.47 
63 
B 23.38 7.8 6.5 5.7 
64 
B 29.38 7.4 6.1 6.7 
65 
B 23.23 7.4 5.8 5.6 
                                   
 
 
 
66 
B 23.88 9.2 6.4 4.7 
67 
B 28.69 8.4 6.8 3.5 
68 
B 25.9 7.8 8.1 4.7 
69 
B 30.52 9.6 7.2 5.3 
70 
B 24.12 10.2 7.8 5.4 
71 
B 25.63 8.4 6.1 4.8 
72 
B 28.31 7.6 6.8 6.1 
73 
B 26.03 8.5 6.2 4.5 
74 
B 22.32 7.5 7.4f 5.2 
75 
B 26.02 8.4 6.1 5.4 
76 
B 28.22 5.5 5.8 6.3 
77 
B 24.21 6.4 7.4 6.3 
78 
B 26.51 5.4 5.7 5.3 
79 
B 23.14 7.2 7.2 2.4 
80 
B 29.4 6.7 6.4 6.1 
